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ABSTRACT 
THE DISCOVERY AND STUDY OF FLUVIRUCIN B1 POLYKETIDE SYNTHASE 
 
SEPTEMBER 2014 
 
TSUNG-YI LIN, B.S., NATIONAL TAIWAN UNIVERSITY 
 
M.S., ANATOMY AND CELL BIOLOGY, NATIONAL TAIWAN UNIVERSITY 
 
Ph.D., CHEMISTRY, UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Nathan A. Schnarr 
 
Rapidly decreasing numbers of viable therapeutic leads in the pharmaceutical pipeline 
demand new, sustainable methods for improved drug discovery and development.  Despite vast 
improvements in de novo drug design and target recognition, Nature remains the richest source 
of small molecule therapeutics.  Among many natural products, polyketides are not only the most 
promising ones for developing new antibiotic leads, but also exhibit unusually high therapeutic 
value ranging from clinical use as anticancer, antiviral, and immunosuppressant drugs.  
Modular polyketide synthases (PKSs) are dedicated nano-machinery that can be 
manipulated to produce a structurally diverse library for drug discovery programs. The ability to 
manipulate these natural systems to produce novel metabolites rests largely on increased 
mechanistic understanding of how these molecules are generated and how these processes can 
be manipulated. As impressive as their pharmaceutical properties are, the biosynthetic 
engineering potential of these compounds continues to draw widespread attention from the 
research community.  Although some success has been realized in terms of polyketide structure 
diversification, severe limitations in engineered product output continue to impede efforts 
toward practical combinatorial biosynthesis. This thesis is focused on understanding and 
exploiting a new biosynthetic enzyme assembly and overcoming the engineering hurdles for 
making novel polyketide metabolites.   
 vii 
Fluvirucin B1, produced by Actinomadura vulgaris, is a 14-membered macrolactam active 
against a variety of infectious fungi as well as influenza A. Despite considerable interest from the 
synthetic community, very little information is available regarding the biosynthetic origins of the 
fluvirucins. Herein, we report the identification and initial characterization of the fluvirucin B1 
polyketide synthase and related enzymes. 
The cluster consists of five extender modules flanked by an N-terminal acyl carrier protein 
and C-terminal thioesterases domain. All but one of the synthase modules contain the full 
complement of tailoring domains (ketoreductase, dehydratase, and enoyl reductase) as 
determined by sequence homology with known polyketide synthases. Active site analyses of 
several key components of the cluster are performed to further verify that this gene cluster is 
associated with production of fluvirucin B1. This work will both open doors toward a better 
understanding of macrolactam formation and provide an avenue to genetics based diversification 
of fluvirucin structure. 
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CHAPTER 1. 
INTRODUCTION OF POLYKETIDES, POLYKETIDE SYNTHASE  
AND ENGINEERING OF POLYKETIDE SYNTHASE 
1.1 Background 
The steady rise of drug-resistant bacteria poses one of the most serious health risks in the 
21st century. Deaths due to drug-resistant infections has raised the attention of most public 
health programs in the world, not only since deaths could have impact on human societal 
resources but also treating drug-resistant infections are far more costly for economic reasons.1 
Rapidly decreasing numbers of viable antibiotic leads in the pharmaceutical pipeline demand new, 
sustainable methods for improved drug discovery and development. Despite vast improvements 
in de novo drug design and target recognition, Nature remains the richest source of small-
molecule therapeutics. Among many natural products, polyketides are among the most promising 
for developing new antibiotic leads. 
1.2 Polyketides 
Polyketides are a broad class of structurally diverse and biologically interactive natural 
products which are produced by bacteria, fungi, and plants. They exhibit a wide range of 
pharmacologically properties including antibiotic (erythromycin and its derivatives), anticancer 
(epothilone B), and immunosuppressant (rapamycin) among others (Figure 1).2  
Since their discovery, polyketides have received enormous attention from the scientific 
community. It is estimated that there are about 10,000 known natural polyketides, and 1% of 
them are potent compounds, a significantly higher hit rate than is generally observed for other 
natural product classes (<0.001%). Given that polyketide-derived pharmaceuticals comprise 20% 
 2 
of the top-selling drugs in the world, it is very reasonable to develop viable therapeutic leads 
based on these compounds. However, due to the structural complexity of polyketides, they are 
generally difficult to be synthesized chemically and also troublesome to be produced naturally 
since the producing organisms are often hard to culture. 3,4 
Despite all the difficulties with making polyketides, an alternative methodology has been 
proposed once after the natural machinery for making polyketides was discovered. Previous 
research has shown that polyketides are biosynthesized by repeated condensations from simple 
acyl-derived metabolites followed by varying degrees of reductive modification to render their 
structural and pharmacological diversity. Therefore, understanding the mechanisms involved in 
Figure 1. Representative polyketide structures. Rifamycin, Erythromycin, and 
Tetracycline are antibiotics. Lovastatin is a HMG-CoA reductase inhibitor (cholesterol 
lowering). Epothilone is an antitumor compound. Rapamycin is an immunosuppressant. 
 3 
polyketide biosynthesis can provide the necessary knowledge for manipulating these natural 
enzyme systems to produce novel metabolites. The enzymes responsible for making polyketides 
are known as polyketide synthases, and the mechanism of polyketide biosynthesis is very similar 
to the biosynthesis of fatty acids. 
1.3 Polyketide Synthases  
Polyketides synthases (PKSs) can be categorized into three different types based on the 
protein architecture and biosynthetic schemes. Type I PKSs, also called modular PKSs, are 
composed of multiple catalytic domains that are covalently linked together and they are 
organized as modules to produce macrolides with highly varied structures. Type II PKSs are 
multienzyme complexes assembled by stand-alone monofunctional enzymes, which utilize the 
same catalytic center iteratively to produce a polyketone chain which can be further processed 
into highly aromatized or oxidized products. Type III PKSs, also known as chalcone synthase-like 
PKSs, are homodimeric enzymes that can catalyze the condensation reaction iteratively to 
produce small aromatic molecules without acyl-carrier domains. This dissertation is mainly 
concerned with components from type I PKSs. 
Modular PKSs, whose configurations are reminiscent of an industrial assembly line, 
contain various modules which are composed of similar domains, and the precise composition 
and arrangement determine the molecular make-up of the polyketide products. Each module 
represents a workstation in the assembly line and each domain functions as a worker at that 
workstation.  Domains in a PKS module are responsible for catalyzing individual reactions that not 
only dictate the chain length of the polyketide but also control the functional groups present on 
the polyketide backbone. Hence, the linear setup of modular PKS systems provides the alternative 
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approach, which is to manipulate the modular PKS systems to produce novel metabolites like 
constructing an industrial assembly line for producing new product. 
 The ability to manipulate natural systems to produce novel metabolites rests largely on 
increased mechanistic understanding of how these molecules are generated in the first place. 
Over the past 20 years, a number of research groups have focused on genetic, biochemical, and 
structural properties of PKSs. 5,6  It is well established that modular PKSs utilize simple extender 
units derived from malonyl-coenzyme A to assemble 
polyketides in a linear fashion. Among several 
characterized PKSs, the biosynthesis of the polyketide core 
of erythromycin A, 6-deoxyerythronolide B (6-dEB) (Error! 
Reference source not found.),  has provided the paradigm 
for understanding the structure and function of the PKSs 
that are responsible for assembling complex polyketides.7 
1.3.1 DEBS for Elucidating the Mechanisms of Polyketide Synthase 
The 6-deoxyerythronolide B synthase (DEBS), which catalyzes the formation of 6-dEB, 
consists of three large subunits, DEBS1, DEBS2 and DEBS3, each containing two modules greater 
than 300 kD in size. A module is defined as the collection of enzymes required for elongation and 
processing of each intermediate structure.  There are 2 domains in the N-terminal loading module, 
responsible for priming the synthase with a propionate starter unit, and 26 domains in the six 
extender modules. Each extender module contains at least three essential domains: a 
ketosynthase (KS), an acyl transferase (AT), and an acyl carrier protein (ACP). The AT domain 
selects the appropriate carbon extender unit and transfers the units from an acyl-CoA to the 
phosphopantetheine (Ppant) arm of ACP. The KS domain accepts the polyketide chain from the 
Figure 2. Structure of 6-dEB. 
 5 
previous module and catalyzes chain elongation reaction by adding an ACP-bound extender unit 
through decarboxylative condensation (Figure 3). 
After the extender unit is added, it can be further processed by optional tailoring domains, 
including ketoreductases (KRs), dehydratases (DHs), and enoyl reductases (ERs), to yield a 
hydroxyl, enoyl, or methylene group at the β-position. Finally, the thioesterase (TE) domain that 
is located at the C-terminus of DEBS module 6 promotes the macrocyclization event which 
releases the final product, 6-dEB. From this mechanistic insight, it is clear that the order of 
catalytic domains in a PKS module determines the structure and processing of the extender unit, 
while the number of PKS modules dictates the size of the polyketide chain. The mechanistic logic 
behind polyketide biosynthesis bodes well for rational manipulation of product structure. As a 
Figure 3. Schematic diagram of 6-deoxyerythronolide B synthase (DEBS). DEBS contains 
three polypeptide units each consisting of two modules which add two carbons to the 
polyketide backbone, as illustrated. A loading didomain (LDD) delivers the propionate 
starter unit to module 1. The thioesterase (TE) domain is responsible for cyclization/release 
of the final product. KS = ketosynthase, AT = acyl transferase, ACP = acyl carrier protein, KR 
= ketoreductase, DH = dehydratase, ER = enoyl reductase. 
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result, several groups have shown that genetic engineering of polyketide biosynthetic pathways 
provides an attractive means of producing new polyketides.  
1.4 Heterologus Expression and Genetic Engineering of Polyketide Synthase Genes  
As mentioned above, modular PKS systems like DEBS provide ways to modify any portion 
of the polyketide through altering the corresponding domains or modules on the genetic level. 
However, several aspects need to be taken into account to make new polyketides. Firstly, one 
needs to demonstrate that the expression of large multi-domain proteins is not hindered by the 
host cell machinery, and secondly, that the post-translational modification of ACP can be properly 
loaded by the phosphopantetheinyl transferase in the host organism. Thirdly, some precursor 
biosyntheses are not universally available (methyl- and ethyl- malonyl CoA) and they may hinder 
the polyketide production. Lastly, one needs to consider the transportation of the precursor and 
product recovery. 
The DEBS genes, isolated from the bacterium Sacchapolyspora erythraea, were cloned 
independently by two groups in the early 1990s, 8,9 and were the first set of polyketide genes 
expressed in a heterologous host. The DEBS system was expressed in Streptomyces coelicolor 
CH999, a strain containing a chromosomal deletion of the entire actinorhodin biosynthetic gene 
cluster, and was used as the host strain to prove the idea of heterolougus production.10 Later, 6-
dEB was further produced in an engineered E. coli strain, BAP1, which was engineered from an E. 
coli-strain BL21 to encode the sfp gene, a promiscuous phosphopantetheinyl transferase from B. 
subtilis. The discovery of the sfp gene solves the problem of the posttranslational modification 
required for the ACP domain.3 Since then BAP1 is the primary E. coli strain serving as the 
heterologous host for expressing polyketide synthase genes.  
 7 
To date, a number of PKSs have been cloned, analyzed, and engineered by recombinant 
DNA technology to make novel “unnatural” products. In DEBS, inactivation of specific domains 
has been accomplished through site-specific mutagenesis. Additionally, domain deletions, 
additions, and swaps have been achieved via genetic engineering efforts (Figure 4).11 Because the 
polyketides synthesized by these modular PKSs resemble each other, strategies have been 
developed whereby modules of one PKS would recognize and process the structurally related 
intermediates from other PKSs. To elaborate, they can be applied into: 
1. Manipulation of polyketide chain length: For reducing chain length, it was reported 
that unnatural triketide and hexaketide lactones could be biosynthesized by a 
Figure 4. Schematic diagram of genetic engineering strategy for producing novel 
compounds from DEBS1 modules 
 8 
deletion mutant comprising DEBS modules 1 and 2 + TE and modules 1 to 5 + TE 
respectively, indicating that TE can act on a variety of chain lengths (C6–C15)12.  For 
extending chain length, four different novel octaketides were biosynthesized by 
adding rapamycin module 2 or 5 between DEBS modules 1 and 2.13 
2. Manipulation of building blocks: As preivously mentioned, incorporation of the 
carbon extender unit is determined by the AT domain. As a result AT is the most 
common domain engineered for domain replacement, in which the native AT domain 
is replaced with another AT with different starter or extender unit specificity. For 
example, nearly all six of the methylmalonyl-specific AT domains in DEBS have been 
successfully replaced by malonyl-specific AT domains from the rapamycin PKS to 
generate 6-dEB or erythromycin analogs lacking the corresponding methyl 
branches.14-17   
3. Manipulation of the β-carbon processing activities: In this category, all of the 
strategies mentioned above have been applied in DEBS manipulations. More 
specifically, inactivation of the ER domain in module 4 can generate the olefin at C-6-
7 of the erythromycin derivative.18 Deletion of the KR domain in module 5 generates 
a C-5 keto derivative of 6-dEB19 and the swap of the KR domains in modules 2, 5, and 
6 with rapamycin DH+KR produces C-10-11, C-4-5, and C-2-3 olefin derivatives of 6-
dEB.20 Similarly, the replacement of KR domain in modules 2 with a DH+ER+KR unit 
results in C-10 deoxy 6-dEB analogs.16 
Furthermore, combining heterologous PKS domains into DEBS can create functional 
hybrid PKSs and result in multiple modifications of 6-deoxyerythronolide B as well as generating 
over 100 novel analogs.16, 21 The approaches further indicate that the modules of DEBS can be 
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altered separately, expressed on different plasmids and combined together to produce unnatural 
polyketide products. 
1.5 Polyketide Synthase Engineering Hurdles 
However, PKS engineering is not always successful. For example, the target compounds 
of domain addition strategies have only about 3–5% production efficiency compared to the 
normal polyketide products. In fact, the parent “unextended” polyketide is the major product 
because the extension module is bypassed within the DEBS multienzyme system. In an attempt 
to alter AT domains, McDaniel and coworkers failed to engineer a malonyl-AT domain in DEBS 
module 4 by using several different domain junctions.22 In the multiple modification experiments, 
the yields of the modified products dropped significantly when the number of combined 
mutations increased and, discouragingly, only 5 of the 21 triple mutant combinations reached 
detectable levels of polyketides, which may mean that multiple modifications on the polyketide 
structure are generally disfavored with this system. 
Previous efforts have pointed out that the substrate selectivity and protein-protein 
interactions within a module or between modules play critical roles in polyketide biosynthesis. 
Because the strategies described above often require making changes in module composition to 
achieve the desired polyketide structure modifications, it is likely that the diminishing yields come, 
at least in part, from the disruption of 3-dimensional protein architecture. 
1.6 Hypothesis 
Successful biosynthetic engineering efforts will undoubtedly require methods which do 
not disrupt native protein architectures. The idea was bolstered by comparison of the inactivation 
and deletion of the KR6 domain in DEBS. A point mutation at the catalytic serine residue gave only 
the targeted analog, whereas the deletion of the whole domain affected the specificity of the 
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adjacent AT domain and led to unexpected products.23   To achieve this, techniques must be 
implemented where maximum product diversity can be achieved through manipulation of existing 
enzyme activities without introducing heterologous components.   However, many fashionable 
assemblies lack the elaborate modular compositions necessary to access the full range of 
functionalities.  For instance, DEBS module 4 is the only module in that system containing all three 
tailoring domains (KR, DH, and ER) similar to mammalian fatty-acid synthase (FAS).24-28   All others 
possess, at most, a single KR which limits the possible chemical outcomes to either the naturally-
formed hydroxyl moiety, or a ketone functionality if the KR is inactivated.  In contrast, module 4 
is capable of producing methylene, olefin, hydroxyl, and ketone groups simply by mutating active-
site residues while keeping the overall 3-dimensional structure intact (Figure 5). With this in mind, 
our strategy relies on discovery and characterization of PKS systems harboring KR, DH, and ER 
domains in the majority, if not all, of the active modules to maximize product diversification. As 
these synthases naturally produce less pharmaceutically-desired, hydrophobic molecules, they 
have generally received little attention so the PKS modules with the full array of tailoring domains 
(KR, DH, and ER) are relatively rare amongst PKSs studied to date. The content of this dissertation 
Figure 5. Schematic diagram of a mutational inactivation strategy for production of novel 
compounds from modules containing the full compliment of β-processing domains. Alterations 
in chemical structure are designed at the genetic level 
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will establish these biosynthetic machines as a powerful means to generate increased product 
diversity and, ultimately, improved small-molecule drugs. 
Recognizing that the flow of intermediates along a given PKS requires, in large part, 
effective communication between neighboring enzymes, many groups have focused on 
determining the associated recognition motifs that govern these interactions.29-31  One of the 
current research thrusts in the field involves redesigning individual modules by swapping primary 
sequence information, including these recognition motifs, in an effort to improve enzyme kinetics.  
Although successful implementations of this approach are beginning to emerge, we thought that 
there must be a way of obtaining product diversity without having to reinvent what Nature has 
already provided. To do so, a strategy where product diversification is solely the result of domain 
inactivation must be implemented. By leaving all recognition interfaces in their natural forms, the 
problem of producing and shuttling intermediates along the synthase is reduced to one of 
substrate selectivity.  In addition to delivering improved yields of engineered products, such a 
system will, for the first time, provide a systematic means of assessing the relative contribution of 
substrate selectivity to the flow of structures from one module to the next in a full-length PKS. 
In summary, the detail of this dissertation provides two vital missing pieces to the 
polyketide engineering puzzle: 1) A unique PKS where a wide variety of polyketide structures can 
be generated without introducing heterologous domains or linkers and 2) a facile method for 
examining ketosynthase substrate tolerance using simple, and readily obtainable, thioester 
substrates.  The former takes advantage of the fact that the FAS-like PKS modules produce β-keto, 
β-hydroxyl, and β-olefin functionalities on the way to the final β-methylene product.  Therefore, 
to access these desired intermediate structures, one must simply “turn-off” the appropriate 
tailoring domain within the module via site-directed mutagenesis.  Most importantly, all protein-
protein interactions and native linkers remain intact, thus allowing for direct determination of the 
 12 
relative impact of chain transfer (in other words, KS substrate selectivity) on engineered 
polyketide production.  
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CHAPTER 2.  
THE NEW TOOL FOR PKS ENGINEERING: FLUVIRUCIN B1 PKS  
AND GENOMIC INFORMATION ANALYSIS 
2.1 Introduction  
Over the past several decades, researchers have devised numerous methods for 
manipulating PKS processes in an effort to diversify product structure and, ultimately, biological 
activity 1 - 5 . Although some success has been realized toward this end, decreased yields of 
engineered products have limited the scope and efficacy of these methods.  At this point it is clear 
that the two primary factors leading to low yields are substrate selectivity of downstream 
enzymes and disruption of protein-protein interactions when heterologous enzymes are 
introduced.6-11 To circumvent the latter, strategies are needed where genetic alterations can be 
introduced without disrupting the native three-dimensional PKS architecture. 
For modular polyketide synthases this means unearthing assemblies which bear the full 
complement of tailoring domains (KR, DH, and ER), similar to mammalian FAS, in most, if not all, 
active modules. Carefully executed mutagenesis of key active site residues should result in all 
possible β-functionalities while leaving the native protein-protein interactions intact (Figure 6).  
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Therefore, PKSs that produce largely unfunctionalized polyketides (i.e. methylenes at most β-
positions) may provide optimal engineering potential.  
2.2 Fluvirucin B1 PKS  
Fluvirucin B1 is 14-membered macrolactam produced by Actinomadura vulgaris with 
moderate to good antifungal and antiviral 
activities (Figure 7).12-14 Following assembly 
of the core macrocycle, a single 3-amino-
3,6-dideoxy-L-talopyranose is appended to 
the sole exocyclic hydroxyl group.  The lack 
of additional ring functionalities peaked our 
interest as we hypothesized that nearly all 
Figure 6. Schematic diagram of a mutational inactivation strategy for production of 
novel compounds form fatty acid-like PKS modules.  Alterations in chemical structure 
are designed at the genetic level. 
Figure 7. Structure of fluvirucin B1 aglycone and 
fluvirucin B1 
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active modules should contain the FAS-like domain organization where KR, DH, and ER are all 
present.  If one were to consider PKS systems as evolutionarily connected to FAS, the fluvirucin 
synthase may represent an early link between the two.  As a result, we were motivated to explore 
the biosynthetic origin of fluvirucin B1 with the ultimate goal of providing a platform for polyketide 
engineering that circumvented the need for incorporation of heterologous domains to achieve 
maximal product diversity. 
2.3 Results and Discussions 
2.3.1 Hypothesis  
From the core structure of fluvirucin B1, we hypothesized that the producing PKS would 
consist of five extender modules assuming that a β-alanine derivative is used as a starter unit in 
the process.  The sole hydroxyl group would therefore arise from a module harboring only a KR 
domain while all other extender modules would contain the full compliment of KR, DH, and ER 
domains (Figure 8).  Based on the positions of macrolactam ring substituents, we expected that: 
(1) the first and last modules contained ethylmalonyl-specific AT domains, (2) the second and 
fourth modules incorporated malonyl groups, and (3) the third module utilized methylmalonate 
(Figure 8).  Finally, ring closure was most likely achieved via a C-terminal thioesterase (TE) domain 
as is the case with similar macrocyclic polyketides.15-17 To test these hypotheses and determine 
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the precise arrangement of enzymes within the assembly, we set out to identify and characterize 
the fluvirucin B1 biosynthetic gene cluster. 
2.3.2 Genomic Sequencing and Bioinformatic Analysis 
To do so, the producing organism, Actinomadura vulgaris, was cultured following 
published procedures.12-14 Genomic DNA was isolated and sequenced (Beckman Coulter 
Genomics) affording 436,311 overlapping sequence fragments.  These sequences were partially 
assembled resulting in 444 consensus sequences ranging in size from 5000 to 170,000 base pairs. 
We then utilized bioinformatic analyses to identify open reading frames that containing PKS 
proteins or domains in silico translation. The relatively large size of PKS constructs allowed us to 
quickly identify potential hits by searching each assembled sequence for open reading frames of 
Figure 8. Predicted tailoring domains and AT selectivities for each fluvirucin B1 synthase 
module based on the fluvirucin B1 aglycone structure 
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at least 4000 base pairs.  Our search identified several PKS gene clusters, one of which contained 
the expected size and module composition of the proposed fluvirucin PKS. 
For the proposed fluvirucin PKS, we initially found 5 contigs (33, 60, 1912, 3721, 3776) 
partially covering the putative PKS gene cluster (Figure 9).   As it shows in Figure 9, the putative 
gene map, it consists of two uncertain areas to be further investigated. For the first gap between 
the contig 3721 and 33, we performed a genomic PCR experiment to obtain the missing sequence. 
Two primers were designed for this purpose: forward primer (ATCTCGACTGCTACGCATCC) is at 
the putative DH domain sequence of module 3; reverse primer: (CCCGAAGTTGGATTTGACC) at the 
putative KS domain in module 4. The PCR experiment was successful, and we isolated an amplicon 
(4524 bp) and then further sequenced it to confirm that the missing gap was indeed flanking by 
the contig 3721 and 33. For the second gap, we conducted a less stringent search within the 
contigs we established, and we found that the contig 112 containing a putative crotonyl-coa 
reductase and some similar sequence to module 2 within contig 3776. We then manually adjusted 
Figure 9. Putative gene cluster of fluvirucin PKS. FluA: module 1 and 2; FluB: module 3 and 
4; FluC: module 5; D: Decarboxylase; G: Glycosyl tranferase; R: PKS regulator; P: proline 
iminopeptidase 
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the sequence information based on the frequency and the degree of disagreement, and we 
proposed the new putative gene culster of fluvirucin B1 PKS (Figure 10). 
2.3.3 Fluvirucin B1 PKS Genes 
Three modular PKS genes, flu A-C, were found to contain an arrangement and 
composition of domains consistent with the expected fluvirucin PKS assembly (Figure 10).  
In addition, several PKS-associated genes were uncovered within the cluster including a 
Figure 10. Gene organization for the fluvirucin B1 PKS cluster. The table summarizes the 
gene cluster organization and gene products identified along with comparison to known 
homologs. 
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pair of transciptional regulators (fluE, fluG), a glycosyl transferase (fluF), a decarboxylase 
(fluI), and a drug transporter (fluD) (Figure 10).  The fluJ sequence shows high similarity to 
crotonyl-CoA reductases and likely plays a role in ethylmalonate generation as is required 
for fluvirucin B1 biosynthesis.  
FluA contains modules 1 and 2 of the fluvirucin B1 assembly. As expected, module 
1 has the full compliment of tailoring domains (KR, DH, and ER) while module 2 possesses 
only a KR domain putatively leading to the sole hydroxyl group on the macrolactam ring.  
A single loading ACP is found at the N-terminus of FluA similar to the vicenistatin PKS 
which utilizes an α-methyl-β-alanine starter unit.18 
FluB contains modules 3 and 4 of the fluvirucin B1 PKS.  Both modules contain KR, 
DH, and ER domains as would be predicted from the fluvirucin core structure.  Finally, 
FluC consists of module 5 and a C-terminal TE domain.  Module 5 again has all three 
tailoring domains consistent with the lack of functionality at the corresponding 
macrolactam ring position.  As described in detail below, modules 1, 3, and 5 are 
extremely similar to each other in terms of primary structure as are modules 2 and 4 but 
similarities drop significantly when comparisons are made between these two groups 
(Group1-module 1, 3, 5; Group2-module 2, 4).  It is therefore tempting to speculate that 
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the fluvirucin B1 synthase is composed of modules arising from two separate evolutionary 
ancestors; one leading to modules 1, 3, and 5 and another leading to modules 2 and 4. 
2.3.4 AT Selectivities 
Extender unit selectivity for AT domains provides compelling evidence for any link 
between a given PKS assembly and its associated polyketide product.  Using, the SEARCHPKS 
program developed by Mohanty and coworkers, probable coenzyme A substrates were 
determined for each of the five putative fluvirucin B1 synthase AT domains.19 To our delight, all of 
the predicted AT domain specificities were consistent with the fluvirucin B1 core structure (Table 
1).  Specifically, modules 2 and 4 showed high sequence similarity with malonyl-specific AT 
domains while module module 3 was predicted to utilize methylmalonyl-CoA.  Modules 1 and 5 
returned a single hit for ethylmalonate specificity amidst several methylmalonyl-specific AT 
domains.  This is most likely due to the considerably lower abundance of ethylmalonyl-specific 
ATs relative to methylmalonyl-specific ones rather than a true indication of relaxed specificity.  
These results, together with the observed tailoring domain patterns, provided the necessary 
evidence to link this polyketide synthase with the biosynthesis of fluvirucin B1. 
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Table 1. Expected AT Specificities : Results from SEARCHPKS 
Mod 1 
Mod2 
Mod3 
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Mod4 
Mod5 
 
2.3.5 KR Domains  
The Keatinge-Clay lab previously uncovered primary sequence patterns associated with 
different types of ketoreductase domains commonly found in modular PKS systems. 20 
Examination of the fluvirucin KR sequences within this context revealed that all five align with the 
B1-type KR sequence pattern (Figure 11). This KR family is generally observed when the KR works 
in concert with other tailoring domains such as DH and ER, which is again consistent with the 
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expected enzyme composition for fluvirucin PKS modules 1, 3, 4, and 5. Interestingly, the module 
2 KR domain also shows B1-type sequence character despite the absence of DH and ER domains 
from that module. This observation may further highlight the fascinating evolution of the 
fluvirucin synthase as discussed below. These results, together with the observed tailoring domain 
patterns and AT selectivities, provided the necessary evidence to link this polyketide synthase 
with the biosynthesis of fluvirucin B1. 
2.4 Experimental detail 
2.4.1 Bacterial strains, culture conditions and DNA purification. 
Actinomadura vulgaris was purchased through American Type Culture Collection (ATCC) 
by the accession number ATCC 53715 and used as the source of DNA for shot-gun sequencing 
Figure 11. Protein homology analysis of Flu-KR Sequence. KR domain comparison 
between Fluvirucin modules and other B1 type KR domains. The homology analyses are 
done by Clustal Omega method of EMBL-EBI website, compared with the results in the 
reference. (Note: DH, functional; dh, nonfunctional PKS abbreviations: Ave: Avermectin, 
Tyl: Tylosin, Asc: Ascomycin, Rap: Rapamycin, Flu: Fluvirucin B1 
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service and the cloning of Fluvirucin B1 polyketide synthase. The strain was cultivated at ambient 
temperature in the liquid medium of ATCC Medium 172 (N-Z Amine with Soluble Starch and 
Glucose), which contains 1% glucose, 2% soluble starch, 0.5% yeast extract, 0.5% N-Z amine type 
A (Sigma C0626), 0.1% CaCO3. The growth of A. vulgaris in ambient temperature can be observed 
after 3 days of culture. For genomic DNA extraction purpose, A. vulgaris was cultured for 6 days, 
and then genomic DNA was extracted by using the MasterPure gram-positive DNA purification kit 
(Epicenter, Madison, WI) 
2.4.2 Genomic sequencing and bioinformatic analysis  
The genomic DNA of Actinomadura vulgaris was collected and sent to Beckman Coulter 
Genomics for the genomic services as the requested concentration (20mg total). Later, the 
436,311 sequence fragments of genomic DNA were sent back and subsequently imported into 
Geneious software (http://www.geneious.com/download). We then did the assembling function 
to harvest 444 contigs to be further analyzed. We chose 4000bp as a cut-off value for open reading 
frames and did in silico translation for those to obtain putative protein products. The putative 
proteins were then analysis by protien BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) for 
screening domains related to PKS. We found several gene clusters resemble to PKS function but 
only 5 contigs fit into what we hypothesized for fluvirucin B1 PKS. 
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The protein sequences of AT domains were defined by BLAST, and subject to the analysis 
tool of SEARCHPKS (http://www.nii.res.in/searchpks.html). And the KR sequence were also 
defined by BLAST and the homology study were done by using ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/), a general purpose multiple sequence alignment 
program for DNA or proteins. 
2.4.3 Genomic PCR Procedure 
The PCR reaction for the gap between module 3 and module 4 was performed in a 50 ul 
reaction mixture containing: 1X Phusion GC buffer, 0.2 mM dNTP, 0.3 mM MgCl2, 3%DMSO, 1 uM 
of each primer (forward primer: ATCTCGACTGCTACGCATCC; reverse primer: 
CCCGAAGTTGGATTTGACC), 1U Phusion Hot Start II DNA polymerase (Thermo scientific, USA) and 
approximately 450ng of genomic DNA was added as template. 
The thermal cycler (Mastercycler ep gradient, Eppendorf) was programmed according to 
the following “2-steps” amplification profile: 3 min denaturation at 98°C, then 10 initial cycles of 
10 s denaturation at 98°C, 5 min annealing and elongation at 72°C, followed by 27 cycles of 10 sec 
denaturation at 98°C, 5 min + (5 sec/cycle) elongation at 72°C, and a final extension step at 72°C 
for 5 min. The amplified DNA fragments (4524bp) were then subjected to 0.8% agarose gel and 
single bands were excised and purified using QIAquick Gel Extraction Kit (QIAGEN, Germany) 
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according to the instructions from the manufacturer. The amplified DNA fragments were then 
purified, and directly inserted into the plasmid vector PCR-Blunt II Topo (Zero blunt TOPO PCR 
cloning kit, Invitrogen). Finally the resulting plasmid was sequenced under regular procedures to 
obtain the genomic information. 
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CHAPTER 3.  
THE CLONING AND HETEROLOGOUS EXPRESSION OF FLUVIRUCIN B1 PKS 
3.1 Introduction  
For the past decade, the biosynthesis community has struggled to capture the true 
engineering potential of polyketide synthases despite a vast array of tools for separating, fusing, 
and rearranging the component enzymes. Of the many techniques employed in reengineering 
PKSs, three stand out as the primary means of genetic alteration: (1) Domain Swapping, (2) 
Domain Addition, and (3) Domain Deletion/Inactivation (Figure 12). 
Domain Swapping:  This technique involves physically replacing an individual PKS enzyme 
with one from another synthase.  Most commonly used for AT domains, the key to effective 
domain swapping is a comprehensive knowledge of domain boundaries such that the surrounding 
enzymes are unaffected.  The primary downside to this procedure is that heterologous domains 
often behave differently in their new environment.  For instance, relaxed substrate selectivity has 
been observed for swapped AT domains leading to diminished yields of the desired polyketide 
products.1-2 
Domain Addition:  This technique is generally employed when an increase in enzyme 
activity is desired.  Many attempts have been made to incorporate KR, DH, and ER domains into 
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modules where they are absent, but the most effective strategy for domain addition involves 
replacing the entire module with a heterologous one bearing the appropriate tailoring domains.  
Figure 12. Schematic diagram of polyketide engineering strategies.  Left to right: Domain 
deletion – KR knockout in DEBS module 2 results in a ketone functionality in place of the 
native hydroxyl group. Domain swap – substitution of a malonyl-specific AT for the native 
methylmalonyl-specific AT results in loss of a methyl group. Domain addition – replacement 
of the native KR domain with a DH/ER/KR cassette results in loss of a hydroxyl group from the 
final product.  The latter two strategies require introduction of heterologous domains leading 
to disruption of native protein-protein interactions.  We seek a PKS where domain deletion 
alone can provide maximal product diversity. 
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In both cases, interaction issues between native and heterologous components often impede the 
flow of intermediates within and between modules, resulting in significantly decreased product 
yields.   
Domain Deletion:  As the simplest technique of the three, domain deletion/inactivation is 
functionally the opposite of domain addition.  The activity of any module containing at least one 
tailoring domain (KR, DH, or ER) can be altered via mutation of active site residues or removal of 
the entire enzyme.  It has been shown, however, that mutation (inactivation) provides 
significantly higher product yields compared to removal (deletion), owing largely to the fact that 
the former method maintains the native three-dimensional structure of the engineered module.3  
This observation provided much of the initial motivation for this proposal and taking together 
with the domain addition and swapping data, it is clear that disruption of PKS structure and 
recognition motifs plays a significant role in diminished product yields.   
To date, the most successful illustration of polyketide structure-diversification, executed 
by McDaniel and coworkers, resulted in nearly 100 novel analogs of 6-deoxyerythronolide B.4,5 In 
short, specific alterations to module components were genetically combined on unique plasmids 
to produce unnatural polyketide products.  They observed yields of mutant products ranging from 
1-70% of the wild-type 6-deoxyerythronlide B.  It should be noted that in all but 2 single mutants, 
the relative yields were less than 50% and most of these fell into the realm of 20-30%.   As a result, 
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only about one-quarter of the triple mutant combinations afforded detectable levels of 
polyketides.  At this rate, access to the many thousands of conceivable engineered analogs is 
beyond reach, thus underscoring the urgent need for strategies that address the primary 
contributors to low product yields.   
It is clear that decreased chemical output is a consequence of two primary barriers: (1) 
substrate selectivity of downstream enzymes and (2) disruption of protein-protein interactions.  
Engineering strategies that circumvent either or both of these issues will afford much needed 
information regarding their relative contributions to low yields and ultimately lead to vastly 
improved product diversity and output.  However, tackling these engineering obstacles will first 
require an in-depth understanding of their origins.  
Therefore, we proposed a new strategy to overcome this hurdles, and we planned to 
unearth a unique PKS system where a wide variety of polyketide structures can be generated 
without introducing heterologous domains or linkers. The strategy takes advantage of the fact 
that the FAS-like PKS modules produce β-keto, β-hydroxyl, and β-olefin functionalities on the way 
to the final β-methylene product.  Therefore, to access these desired intermediate structures, one 
must simply “turn-off” the appropriate tailoring domain within the module via site-directed 
mutagenesis.  Most importantly, all protein-protein interactions and native linkers remain intact, 
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thus allowing for direct determination of the relative impact of chain transfer (in other words, KS 
substrate selectivity) on engineered polyketide production. 
Upon our previous identification of the gene cluster for making fluvirucin B1, a fatty-acid-
synthase-like PKS system, in Actinomadura vulgaris, it was soon appreciated as an interesting PKS 
system with many unique biosynthesis attributes (Figure 13).6 It contains 5 modules of which 4 
contain the full set of PKS tailoring domains. According to our hypothesis, it is an ideal system for 
Figure 13. Schematic diagram for the putative fluvirucin B1 PKS.  The assembly consists of 
five extender modules flanked by an N-terminal loading ACP and C-terminal thioesterase 
(TE) domain. FluA consists of the loading ACP, module 1 and module 2. FluB consists of 
modules 3 and 4. FluC consists of module 5 and the TE domain. 
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engineering strategy of single domain inactivation via site-directed mutagenesis. As a result, we 
were motivated to explore the biosynthetic origin of fluvirucin B1 with the ultimate goal of 
providing a platform for polyketide engineering that circumvented the need for incorporation of 
heterologous domains to achieve maximal product diversity. Herein, we describe our effort to 
unearth the assembly line of fluvirucin B1 PKS. 
3.2 Result and Discussion 
3.2.1 Cloning of Module 1 of Fluvirucin B1 PKS and PCR Optimization 
To confirm the sequences obtained from partial assembly of the A. vulagaris genome and 
with the ultimate goal of reconstituting the entire assembly in E. coli, we turned our attention to 
cloning each module individually from genomic DNA. We firstly setup a genomic library (~800 
colonies isolated) to screen for the genes that either contributed to or are associated with 
fluvirucin B1 PKS.  Unfortunately, all screening efforts came back with the indication that the 
genomic library of A. vulagaris was contaminated by the genome of E. coli, and we suspect that it 
was contaminated during the preparing processes of the genomic library. 
After the failure of our genomic library, we began seeking alternative ways to clone the 
gene of fluvirucin B1 PKS and one of which is genomic polymerase chain reaction (PCR). For 
replicating the gene of interest from genomic DNA, it is not only hard to get single product but 
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also difficult to amplify a long PCR product (>2kb) with high GC-content because GC-rich sequence 
can easily to form secondary structure and render PCR useless. According to the genomic 
sequencing information, the genome size of A. vulagaris is estimated about 12 million base pair 
(bp), and it is relatively larger than the genome size of Streptomyces strain. For instance, the 
complete genome of S. coelicolor strain A3(2) was decoded and published in 20027, and the 
genome was sequenced about 8 million bp with a GC-content of 72.1%. We expect the GC content 
of A. vulagaris could be as high as S. coelicolor since they are close relatives under the order of 
Actinomycetales, and indeed the sequence analysis showed FluA (11910bp) consists GC-content 
of 71.3%, FluB (13128 bp) and FluC (7191bp) are 71.5% and 71.9% respectively. Considering all 
these difficulties, we began our quest for cloning fluvirucin B1 PKS. Even though there is no 
literature documented for long PCR protocol applied to GC-rich sequence, there are some aspects 
of PCR can be optimized for our purpose. For instance, there are PCR methodologies for 
temperature manipulations, different organic solvents as PCR additives, and primer-design 
techniques, etc. We used all of PCR techniques mentioned above for cloning the assembly line of 
fluvirucin B1 PKS.  
Based on alignment with known PKS constructs and the in-silico analysis of restriction 
enzyme sites, we were able to determine the effective sequence boundaries for each fluvirucin 
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synthase module, and we began designing the PCR experiment and optimizing the PCR method 
for each module.   
For starter, we would like to describe our effort for cloning of module 1. We used the 
sequence of module 1 as our amplification segment (6713bp, from the first ATG to the NotI site 
as the boundary between module 2) and designed the PCR primers from the upstream and 
downstream sequences within 1,000~1,500 bp to the boundaries of module 1. We then took the 
arbitrarily defined sequence to Primer-BLAST on NCBI website to perform the computer-aided 
primer-design in the default setting, and we obtained 20 sets of primers for cloning module 1. 
Subsequently, we screened all the primers obtained above with NetPrimer 
(http://www.premierbiosoft.com/netprimer/) software, and selected the primers scored over 90 
in NetPrimer. So, our first round primers are listed in Table 2: 
As soon as we obtained the 
oligonucleotides in the list for cloning module 
1, we performed several general PCR 
reactions with Phusion Hot Start II DNA 
polymerase. Initially, the primer sets of Avul-
Mod1-F1&R1 and Avul-Mod1-F2&R2 did not 
yield any meaningful products (Figure 14); 
Table 2. The primer list for module 1 
Avul-Mod1-F1: GGACATCGGCGGCGGCTTCG 
Avul-Mod1-R1: GCGGGCGGCCAGGACCATCTT 
Avul-Mod1-F2: CCGACTGCCTCCTGCGGGTG 
Avul-Mod1-R2: GGACGTGGACGCGGCTCGGA 
Avul-Mod1-F3: GCCACCACCAGCATCCGCAT 
Avul-Mod1-R3: GTTCCGCCGATGAAGACGCC 
Avul-Mod1-F4: GCCCTCCCAGTTCGGCTTCG 
Avul-Mod1-R4: GGACTTCACGGTGCCCAGCC 
Avul-Mod1-F5: ATCAACACGCTGGGCGGCAT 
Avul-Mod1-R5: GGTTGGGGAGCACGGTCACG 
Avul-Mod1-F6: TCCGTACCCGATCTCCGCCC 
Avul-Mod1-R6: CCGCCCAGACATGACCGAACTG 
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however, in the following PCR experiment with for the 
permutation of primer matches (F3~F6 matched with 
R3~R6), we observed that Avul-Mod1-F3, F5, F6 are 
promising forward primers, R6 is a very promising reverse 
primer, and R5 only effective when combined with F5 
(Figure 15). Those positive results of our first attempt were 
subjected for the following cloning of TOPO-Blunt method 
in order to identify the sequence of the PCR product, but 
unfortunately the sequencing result did not suggest any 
full-length sequence of module 1.  
Figure 14. The PCR result for cloning 
module 1-a. Lane 1-2: F1+R1, R2; 
Lane 3-4: F2+ R1, R2. No promising 
band observed above 6,000bp. 
Figure 15.  The PCR result for cloning module 1-b. Lane 1-4: F3+R3, R4, R5, R6; Lane 5-8: F4+ 
R3, R4, R5, R6; Lane 9-12: F5+R3, R4, R5, R6; Lane 13-16: F6+R3, R4, R5, R6. Lane 4, 12, 16 
indicated R6 is a good reverse primer; Lane 9, 10, and 12 showed F5 is promising. The same 
conclusion can be deduced on F3 and F6. 
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With the data that some desired amplification of module 1 appeared in the DNA gel 
analysis, we hypothesized that the low yield/non-full length amplification of the PCR experiment 
could be caused by the GC-rich sequence within module 1. It has been suggested that DNA 
amplification by PCR is frequently complicated with low yield and specificity by the GC content of 
the target sequence, and the addition of some organic solvents like DMSO or betaine to PCR could 
improve the amplification of DNA by reducing the secondary structures of GC-rich regions in the 
DNA template or the primers.8 Therefore, we setup several PCR experiments with the primers 
previously identified promising in amplifying the DNA of module 1, and we titrated the 
concentration of DMSO from 0 % to 8 % in these experiment. To our delight, we got very promising 
Figure 16. The PCR result for cloning module 1 with 5% DMSO. Lane 1: F1+R1; Lane 2: F1+ R6; 
Lane 3: F3+R6; Lane 4: F4+R6; Lane 5: F5+R4; Lane 6: F5+R5; Lane 7: F5+R6; Lane 8: F6+R6.
The bands around 8,000bp indicated in Lane 3 to 8 are positive result, and the gel analysis 
confirmed that DMSO indeed improves the amplification of DNA in our experiment. 
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results in the PCR experiment with 5% DMSO (Figure 16). All PCR products with the predicted 
length were excised, and then later confirmed the PCR results from Avul-Mod1-F3 + R6, F5 + R6 
and F6 + R6 are true replications of module 1. Subsequently, we further improved our cloning 
strategy not only by “touch-down” PCR methodology9 but also by designing a forward primer with 
a NheI restriction enzyme site (a non-cutter for module 1), AMod1-NheI-F1 (see experiment 
procedures), and we used in combination with Avul-Mod1-R6 in a similar setup of PCR to obtain 
the pre-module 1 DNA fragment that can be purified, digested, and directly ligated into pET21b 
without further steps of sub-cloning (Figure 17). 
Figure 17. The plasmid map of Flu-module1 (pTL-A01)  
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3.2.2 Cloning of Module 3 and 5 of Fluvirucin B1 PKS 
With our successful experiments of replicating module 1 directly from genomic DNA, we 
moved forward to a new and fast protocol to clone module 3 and 5: design proper primers with 
restriction enzyme sites at the boundaries of each module. For cloning module 3, we designed the 
primers in Table 3:  
 We did similar permutation of primer matches and the same titration of DMSO from 0% 
to 8 % in the PCR for cloning module 3, and we successfully cloned out pre-module 3 DNA with 
7% DMSO by the primer combination of AMod3-EcoRI-F2 and AMod3-R2. Later the PCR products 
were digested and incorporated into pET-21b to obtain pTL-A03 (Figure 18). Next, we applied the 
simple designing principle on primers for cloning module 5 (including the TE domain), we tested 
all the primers listed in Table 4:  
 
Table 3. The primer list for module 3 
AMod3-EcoRI-F1: AAAAAAGAATTCGATGGCCACTGACGACAAGTTC 
AMod3-R1: TTTTTTGACGTGGACGCGGCTCGGAC 
AMod3-EcoRI-F2: AAAAAAGAATTCGATGGCCACTGACGACAAGTTCCGG 
AMod3-R2: TTTTTTGTGGACGTGGACGCGGCTCGGAC  
(Note: restriction enzyme sites were underlined and the additional “in-frame” 
bases were emphasized in boldface.) 
Table 4. The primer list for module 5 
AMod5-NheI-F1: TTTTTTGCTAGCATGGCTGACGAA 
AMod5-HindIII-R1: AAAAAAAAGCTTTCACGCGCCGTT 
AMod5-NheI-F2: AAAAAAGCTAGCATGGCTGACGAAGAGAAG 
AMod5-HindIII-R2: TTTTTTAAGCTTCGCGCCGTTCGA 
AMod5-NheI-F3: AAAAAAGCTAGCATGGCTGACGAAGAGAAGCTCCTC 
AMod5-HindIII-R3: TTTTTTAAGCTTCGCGCCGTTCGAACGCCC 
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The permutation of primer matches were again deployed in order to find the best primer 
set to clone the DNA of pre-module 5, and we observed the promising gel bands by the 
combination of AMod5-NheI-F1 + R2, F2 + R3, F3 + R2, and F3 + R3 (data not shown). However, 
the concentration of DMSO is slightly different than the previous titration for module 1 and 3, 
because the PCR products of pre-module 5 were not amplified until the concentration of DMSO 
was increased to 10%. This suggested that genomic PCR can be done in a relatively high 
concentration of DMSO even if the high concentration DMSO can slightly inhibit the activity of 
Figure 18. The plasmid map of Flu-module3 (pTL-A03) 
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DNA polymerase. In the end, pTL-A05 (Figure 19) was cloned out similarly as previously described 
for module 1 and 3.  
As a summary for section 3.2.1 and 3.2.2, we were fortunately able to clone out Flu-
module 1, 3, 5 directly with properly designed primers and various concentration of DMSO as 
additives in a typical genomic PCR experiment. All three PCR products are amplified correctly and 
verified by BLAST with the method provided in experimental procedures. 
Figure 19. The plasmid map of Flu-module5 (pTL-A05) 
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3.2.3 Cloning of Module 2 of Fluvirucin B1 PKS and the Study of PCR Additives 
Based on the strategy we developed, we applied to the same rules for designing primers 
(Table 5) for module 2; however, we failed to obtain any substantial PCR products with every 
possible match of forward and reverse primers and with different concentration of DMSO from 
0% to 10%. We then hypothesized that the sequence within high GC content in module 2 (5160bp 
with 70.6% of GC content) or the interactions between primers and DNA template may be the 
cause for getting no/non-specific PCR products, and DMSO is not good enough to resolve the 
problem. Therefore, we designed a series tests on PCR additives to overcome this problem. We 
used the PCR condition for cloning module 1 with 8 different organic solvents as PCR additives in 
the concentration range that previously suggested (Figure 20).10,11 
Table 5. The primer list for module 2 (the first round) 
Avul-Mod2-F1 CCACACCGGCAAGATCATCCTC 
Avul-Mod2-F2 CCGGCAAGATCATCCTCACCATG 
Avul-Mod2-F3 CCTCACCCCCGACAAGATCGA 
Avul-Mod2-F4 TTCGTCCTCTACTCCTCCTCGG 
Avul-Mod2-F5 CCTCACCACCACCGACATCAC 
Avul-Mod2-F6 CGACATCACCCGCATCGAACA 
Avul-Mod2-F7 ACCTCGCCACCGAACACCAGAC 
Avul-Mod2-F8 CCTCCCGCCGAGGAGACCAAG 
Avul-Mod2-F9 CGAGGAGACCAAGCCCCCGA 
Avul-Mod2-F10 GCCATCCACCGCCACACCAC 
Avul-Mod2-F11 ACCAACCCAGCGGCATGAGC 
Avul-Mod2-F12 AAGCGGGACGCCCGTTCAAG 
Avul-Mod2-F13 GCGACGCTGGTGTTCGACCA 
Avul-Mod2-F14 AGGACAGGCTTCTGGACGGTT 
Avul-Mod2-F15 GCCACCGAACACCAGACCCG 
Avul-Mod2-F16 CCATCCACCGCCACACCACC 
Avul-Mod2-F17 TCTGCTCGGGGTGGAGGACG 
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Avul-Mod2-F18 GCCTCTCTGCTCGGGGTGGA 
Avul-Mod2-F19 CGGGATGCGGTGCTGGTGTT 
Avul-Mod2-F20 TCGCCATCCACCGCCACACCACC (same as F10 but longer) 
------------------------------------------------------------------------------------------------------ 
Avul-Mod2-R1 GTACTGCTCGGACAGGAGGAC 
Avul-Mod2-R2 GATCGGGAGGTTCCTGAGCTG 
Avul-Mod2-R3 CGAACATGTCCACGTCGTCGT 
Avul-Mod2-R4 GTAGTTGATGCTGCTCGCCAT 
Avul-Mod2-R5 CGTGTGCATCGGCTCGAAGAT 
Avul-Mod2-R6 GTAGTTGGTCTCGTACCCCCAGA 
Avul-Mod2-R7 GCCATCCACAGGTAGCGGTTG 
Avul-Mod2-R8 TAGACGGCGGACAGGGTGGG 
Avul-Mod2-R9 GCCCCGAACCGCTTCCACTC 
Avul-Mod2-R10 TCGGCCTTGTGGTCGCTGGAGA 
Avul-Mod2-R11 ACCTTGTCACCGGCCTGCCA 
Avul-Mod2-R12 GGGCCGGTCTTCAGCACGAC 
Avul-Mod2-R13 TCGGCGTCGTACTGCTCGGA 
Avul-Mod2-R14 GTCAGCCCGACCACACCGTG 
Avul-Mod2-R15 TGTTGAACGCCCCGTCCAGC 
Avul-Mod2-R16 CAGTACCCCGACCTTGCCGCT 
Avul-Mod2-R17 CGGCGTCGTACTGCTCGGAC 
Avul-Mod2-R18 GATCGGCGTTCTCCAGGGCG 
Avul-Mod2-R19 CGGCGATCTCCTCGGGTTGC 
Avul-Mod2-R20 GCCATCCACAGGTAGCGGTTGTCG (same as R7 but longer) 
 We observed that sulfolane offers more specific amplification whereas glycerol provides 
with the best yield among all. After we found these phenomena/characteristics of organic 
solvents in genomic PCR are superior to DMSO alone, we made a new PCR recipe consists of 15% 
glycerol and 0.6M sulfolane as a new PCR additive mix for cloning module 2 with the primers 
previously designed.  
Followed by series of PCR experiments, nevertheless, we observed some improvements 
in terms of specificity (data not shown), but we could not harvest enough DNA of pre-module 2 
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to be subjected into expression vector. Later, we designed the second round of primers for cloning 
module 2 (Table 6), and we successfully cloned out the DNA of pre-module 2 with the primer 
combination of Avul-Mod2-pF6+R7 and pF6+R17. The DNA of pre-module 2 was finally sub-cloned 
into pET21b to construct the expression vector of Flu-module2, pTL-A02 (Figure 21). 
  
Figure 20. The gel analysis of PCR additives examination based on module 1 PCR setup. All 
panels contain 4 different concentrations and 1 lane of molecular marker 
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Table 6. The primer list for module 2 (the second round) 
Avul-Mod2-pF1: CCATCAACACCCACACCCTCAG 
Avul-Mod2-pR1: CCATCCACAGGTAGCGGTTGTC 
Avul-Mod2-pF2: GCGTTCGTCCTCTACTCCTCCT (mis-primed at the end of mod4) 
Avul-Mod2-pR2: AGGTAGCGGTTGTCGTACTGGTG (overlap with R7) 
Avul-Mod2-pF3: TCATCCACATGTCCGTTATCGCAG 
Avul-Mod2-pR3: ACCGTGTTGTAGTTGATGCTGCTC 
Avul-Mod2-pF4: AACTGCTGGACCTGTTCGCCT 
Avul-Mod2-pR4: CTCATCCTCCGCAAGCTAGTTGTC 
Avul-Mod2-pF5: GGATGTGGTGCTCAACTCGCTG 
Avul-Mod2-pR5: TGAGGCCGTAGAAGACGCTG 
Avul-Mod2-pF6: CCCATCAACACCCACACCCT 
Avul-Mod2-pR6: TCCGCAAGCTAGTTGTCCGA 
Avul-Mod2-pF7: ATCACCCGCATCGAACAAGCC 
Avul-Mod2-pR7: TTGAGGCCGTAGAAGACGCTG 
Avul-Mod2-pF8: TGGATGTGGTGCTCAACTCGCT 
Avul-Mod2-pR8: GTGTTGTAGTTGATGCTGCTCGCC 
Avul-Mod2-pF9: AGATGCTCGCCGAACTGCTG 
Avul-Mod2-pR9: TTGATCTGGTCGATGTGGCGG 
Avul-Mod2-pF10: CACACCGGCAAGATCATCCTCAC 
Avul-Mod2-pR10: ACGTCGCCGACCTTGATCTG 
Avul-Mod2-pF11: AGGCAACCAACTCCTCGACACCGCCCT 
Avul-Mod2-pR11: AACTCCGTGACCGCTGACCGCACCA 
Avul-Mod2-pF12: ACGCCGGACACGACCGTATTGGGCAGA 
Avul-Mod2-pR12: TCCCGTTCACGCCGCCGACGTTGTT 
Avul-Mod2-pF13: TCCAAGCGGGACGCCCGTTCAAGGA 
Avul-Mod2-pR13: TGGTCGATGTGGCGGGCACGGAACT 
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3.2.4 Cloning of Module 4 of Fluvirucin B1 PKS 
As our effort for cloning module 1, 3, 5 and 2 being made, we simultaneously conducted 
similar experiments for cloning module 4. We designed more than 70 primers (see 3.4 
supplement section for the complete list) and tested in PCR experiments with DMSO or with 
glycerol/sulfolane mix, but we could not flank any desired products after more than 2,000 PCR 
run and ~200 gel analyses were casted. Then we reached to a conclusion that it may not be 
realistic to directly clone module 4 as one piece in genomic PCR, we hypothesized that module 2 
Figure 21. The plasmid map of Flu-module2 (pTL-A02). 
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and 4 may have the same evolution origin which makes them hard to be distinguished in the 
amplification of genomic PCR. As a result, we began to seek an alternative way to grasp module 4 
out of the sea of genomic DNA, so we adopt the concept of “divide and conquer” by replicating 
module 4 DNA from two separate pieces, if not, as less pieces as possible, and merge each piece 
as the original module 4 DNA by the molecular cloning techniques. 
By performing in-silico analysis for the restriction enzyme site of module 4 DNA, we 
quickly discovered a single cutter, MluI, located in the middle of the sequence, and we were 
convinced that it can be served as a stitch point for ligation reaction. Therefore, we planned to 
amplify two separate fragments of DNA, M4-1f and M4-2f, in genomic PCR and subsequently to 
stitch them together. We then designed the proper primers for cloning each DNA fragment, and 
we successfully replicated M1-4f with AMod4-HindIII-F1 + AMod4h-R6 and M4-2f with AMod4h-
F7 + AMod4-XhoI-R7 (primers).  
After the DNA information of the two fragments were sequenced by primer walking, 
however, we were surprised that M4-1f fragments are about 282bp shorter than we expected! 
Later, we conducted a thoroughly sequence comparison between the short and the expected 
sequence, and we found a repeated sequence, CCACCACCCA, located at the edge of the snipped 
sequence. We later recognized that the region is occupied with high content of C or G, which could 
contribute to secondary structure or G-quadruplex.12 
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In order to solve the problem, we lowered the concentration of Mg+2 in PCR reaction and 
extended the length of our primers, and we finally obtain the full length of M4-1f with AMod4-
HindIII-F8 + AMod4h-R10. Subsequently, M4-1f and M4-2f were ligated together to harvest 
preM4 DNA, and the preM4 DNA was digested by NotI/XhoI and integrated with pET-21b to obtain 
pTL-A04 (Figure 22).  
Figure 22. The plasmid map of Flu-module4 (pTL-A04) 
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3.2.5 Protein Expression 
In conclusion, all five modules were cloned separately in pET vectors for expression in E. 
coli. Overexpression of each module was observed in BL21(DE3) cells, and gel migration patterns 
were consistent with calculated protein masses (Figure 23). The fact that E. coli seems to respond 
well to these foreign genes bodes well for our future efforts aimed at generating fluvirucin-
derived structures in this heterologous host. In the near term, the ability to reliably produce 
usable quantities of each module will greatly facilitate studies concerning the substrate 
specificities and enzyme kinetics that govern fluvirucin B1 biosynthesis. 
Figure 23. PAGE analysis of fluvirucin modules overexpressed in E. coli following Ni-NTA affinity 
purification. Lanes are marked with the corresponding protein or blank pET21 vector. Mod = 
Module. Approximate protein molecular weights: module 1 = 230 kDa, module 2 = 185 kDa, 
module 3 = 220 kDa, module 4 = 240 kDa, module 5 = 254 kDa. % acrylamide = 7.0. 
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3.3 Experimental Procedures 
3.3.1 Bacterial Strains, Culture Conditions and DNA Purification. 
Actinomadura vulgaris was purchased through American Type Culture Collection (ATCC) 
by the accession number ATCC 53715 and used as the source of DNA for shot-gun sequencing 
service and the cloning of Fluvirucin B1 polyketide synthase. The strain was cultivated at ambient 
temperature in the liquid medium of ATCC Medium 172 (N-Z Amine with Soluble Starch and 
Glucose), which contains 1% glucose, 2% soluble starch, 0.5% yeast extract, 0.5% N-Z amine type 
A (Sigma C0626), 0.1% CaCO3. The growth of A. vulgaris at ambient temperature can be observed 
after 3 days of culture. For genomic DNA extraction purposes, A. vulgaris was cultured for 6 days 
and then genomic DNA was extracted by using the MasterPure gram-positive DNA purification kit 
(Epicenter, Madison, WI) 
3.3.2 General Procedure for PCR Experiment 
PCR reactions were performed in a 50µl reaction mixture containing: 1X Phusion GC 
buffer, 0.2mM dNTP, 0.3mM MgCl2, 0~3%DMSO, 1M of each primer, 1U Phusion Hot Start II DNA 
polymerase (Thermo scientific, USA) and approximately 300~450ng of genomic DNA was added 
as template. 
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The thermal cycler (Mastercycler ep gradient, Eppendorf) was programmed according to 
the following “3-step” amplification profile: 3min denaturation at 98°C, then 35~40 cycles of 
10sec denaturation at 98°C, 30sec at annealing temp (depending by the primer set), Xmin (X=the 
length of amplfication/1000) elongation at 72°C and a final extension step at 72°C for 3~5min. The 
amplified DNA fragments were then subjected to 0.8%~1.1% agarose gel to verify the products. If 
a single band of desired length were revealed, it would be excised and purified using a QIAquick 
Gel Extraction Kit (QIAGEN, Germany) for any following analysis or cloning procedure. 
3.3.3 Cloning of Module 1 of Fluvirucin B1 Polyketide Synthase 
The PCR reaction for module 1 was performed in a 50µl reaction mixture containing: 1X 
Phusion GC buffer, 0.2mM dNTP, 0.3mM MgCl2, 5%DMSO, 1µM of each primer (AMod1-NheI-F1: 
AAAAAAGCTAGCATGAGCCAGTCCGGAAACAGCGAA; Avul-Mod1-R6: CCGCCCAGACATGACCG-
AACTG), 1U Phusion Hot Start II DNA polymerase (Thermo scientific, USA) and approximately 
450ng of genomic DNA was added as template. 
The thermal cycler (Mastercycler ep gradient, Eppendorf) was programmed according to 
the following “2-step” amplification profile: 3min denaturation at 98°C, then 10 initial cycles of 
10sec denaturation at 98°C, 5min annealing and elongation at 72°C, followed by 27 cycles of 10sec 
denaturation at 98°C, 5min + (5sec/cycle) elongation at 72°C, and a final extension step at 72°C 
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for 5min. The amplified DNA fragments (7221bp) were then subjected to 0.8% agarose gel and 
single bands were excised and purified using a QIAquick Gel Extraction Kit (QIAGEN, Germany) 
according to the instructions from the manufacturer. Subsequently, it was subjected to restriction 
enzyme digestion of NheI and NotI and the digested products were ligated to pre-digested pET-
21b to obtain pTL-A01. 
3.3.4 Cloning of Module 3 of Fluvirucin B1 Polyketide Synthase 
The PCR reaction for module 3 was performed in a 50µl reaction mixture containing: 1X 
Phusion GC buffer, 0.2mM dNTP, 0.3mM MgCl2, 7%DMSO, 1µM of each primer (AMod3-EcoRI-
F2: AAAAAAGAATTCGATGGCCACTGACGACAAGTTCCGG; AMod3-R2: TTTTTTGTGGACGT-
GGACGCGGCTCGGAC), 1U Phusion Hot Start II DNA polymerase (Thermo scientific, USA) and 
approximately 450ng of genomic DNA was added as template. 
The thermal cycler was programmed as for module 1, and the amplified DNA fragments 
(6338bp) were purified, and directly digested by EcoRI and NotI. The digested products were 
ligated to pre-digested pET-21b to obtain pTL-A03. 
3.3.5 Cloning of Module 5 + TE of Fluvirucin B1 Polyketide Synthase 
The PCR reaction for module 5 was performed in a 50µl reaction mixture containing: 1X 
Phusion GC buffer, 0.2mM dNTP, 0.3mM MgCl2, 10%DMSO, 1µM of each primer (AMod5-NheI-
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F3: AAAAAAGCTAGCATGGCTGACGAAGAGAAGCTCCTC; AMod5-HindIII-R2: TTTTTTAAGCTTC-
GCGCCGTTCGA), 1U Phusion Hot Start II DNA polymerase (Thermo scientific, USA) and 
approximately 450ng of genomic DNA was added as template. 
The thermal cycler was programmed as for module 1, and the amplified DNA fragments 
(7196bp) were then extracted and subjected to NheI and HindIII double digestion. Finally, the 
digested products were ligated to pre-digested pET-21b to obtain pTL-A05. 
3.3.6 PCR Organic Solvent Study 
The PCR condition and the operation of thermocycler are the same with the method for 
cloning of module 1, except for the PCR additive was swap with the following organic solvent: 3% 
, 6%, 10%, 15% (v/v) of DMSO; 0.15M, 0.3M, 0.6M, 1M of sulfolane; 5% 10% 15% 20% of glycerol; 
0.5M, 1M, 2M 3M of betaine; 0.25M, 0.5M, 1M, 2M Of 1, 3-butanediol; 0.1M, 0.25M, 0.5M, 1M 
of 1,5-pentanediol; 0.25M, 0.5M, 1M, 2M of xylitol; 0.25M, 0.5M, 1M, 2M of d-sorbitol, are used 
in the PCR reaction. 
3.3.7 Cloning of Module 2 of Fluvirucin B1 Polyketide Synthase 
The PCR reaction for pre-module 2 was performed in a 50 µl reaction mixture containing: 
1X Phusion GC buffer, 0.2mM dNTP, 0.3mM MgCl2, 15% glyerol, 0.5M sulfolane, 1µM of each 
primer (Avul-Mod2-pF6: CCCATCAACACCCACACCCT; Avul-Mod2-R7: GCCATCCACAGGTAGCGG-
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TTG), 1U Phusion Hot Start II DNA polymerase (Thermo scientific, USA) and approximately 450ng 
of genomic DNA was added as template. 
The thermal cycler was programmed according to the following “stepdown” amplification 
profile: 3min denaturation at 98°C, then 10 initial cycles of 10sec denaturation at 98°C, 30sec 
annealing at 72-68°C, 6min elongation at 72°C where the annealing temperature was decreased 
by 0.4°C per cycle, followed by 27 cycles of 10sec denaturation at 98°C, 30sec annealing at 68°C, 
6min + (5sec/cycle) elongation at 72°C, and a final extension step at 72°C for 5min. 
The amplified DNA fragments (6760bp) were then purified, and directly inserted into the 
plasmid vector PCR-Blunt II Topo (Zero blunt TOPO PCR cloning kit, Invitrogen) to obtain pM2-44-
4-3 (pTL-preM2). After obtaining pTL-preM2, the same PCR protocol was performed as stated 
above, except for using the following primers: AMod2-NdeI-F8: AAAAAACATATGACGC-
TGGTGTTCGACCAC; AMod2-HindIII-R1: TTTTTTAAGCTTGGACGCGCCGAGCTGGTC. The DNA 
amplicons (5265bp) were digested by NdeI and HindIII, and then were ligated to pre-digested pET-
21b to obtain pTL-A02. 
3.3.8 Cloning of Module 4 of Fluvirucin B1 Polyketide Synthase 
The PCR protocol for pre-module4 is the same as for pre-module2, except for using the 
following primers: AMod4-HindIII-F8: AAAAAAAAGCTTCGGCAAGATCATCCTGACCATGC and 
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AMod4h-R10: CGGGTACATGCCCAAGGAGTTGA are for M4-1f fragments (5863bp); AMod4h-F7: 
CAACGCACAAGACATCCAACA and AMod4-XhoI-R7: TTTTTTCTCGAGCAGGCCCTGGTCGATC-
AGCGAGAAGAGC are for M4-2f fragments (4339bp). M4-1f fragments and M4-2f fragments are 
separately inserted into the plasmid vector PCR-Blunt II Topo to obtain pTL-M4-1f and pTL-M4-2f. 
Later, the pTL-M4-1f plasmids were digested by HindIII and MluI to obtain M4-1f fragments again 
to clone into pTL-M4-2f to harvest pTL-preM4. 
Finally, the pTL-preM4 was digested by NotI and XhoI and ligated to pre-digested pET-21b 
to obtain pTL-A04. 
3.3.9 General Procedure for Protein Expression and Isolation 
E. coli (BL-21) bearing the appropriate plasmid was grown in 1 L shake cultures of LB-
ampicillin media at 37 °C until the OD600 was between 0.6 and 0.8. Overexpression was induced 
by adding 200 μL of 1 M IPTG at appropriate induction temperature (see below) for 16 h. After 
this point, all work was carried out at 4 °C. Cells were pelleted by spinning at 6000 rpm for 10 min 
and resuspended in 10 mL of lysis buffer (20 mM TrisHCl, 150 mM NaCl, 1 mM Na2EDTA, 1 mM 
EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 
μg/mL leupeptin, pH 8). Cells were lysed for five 30 sec intervals with a 60 sec cool down period 
between each. Lysed cells were spun at 14,000 rpm for 60 min. The lysate supernatant was 
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equilibrated with 3 mL of Ni-NTA bead slurry for 60 min. The mixture was then poured into a 15 
mL column, and the supernatant was eluted. The column was then washed with two 15 mL 
portions of wash buffer (50 mM phosphate, 300 mM NaCl, 50 mM imidazole, pH 8.0) and eluted 
with 3 mL of elution buffer (50 mM phosphate, 300 mM NaCl, 250 mM imidazole, pH 8.0). The 
purified protein was loaded onto a 100 kDa cutoff centrifugal concentrator, diluted to 15 mL with 
storage buffer (100 mM Tris, 1 mM EDTA, 1 mM dithioerythritol, 10% glycerol, pH 8), and spun at 
3000 rpm. Dilution and filtration was repeated a total of three times. Protein concentrations were 
determined by Bradford assay with an average concentration of approximately 500 μM. Proteins 
were flash frozen and stored at −80 °C unl use. 
3.3.10 Materials  
All biochemicals, chemicals, and media were obtained from Fisher Scientific, all restriction 
enzymes were obtained from New England Biolabs, and other molecular biological reagents were 
obtained from Fisher Scientific, New England Biolabs, or Invitrogen. All PCR primers were 
synthesized by Eurofins MWG Operon. 
All DNA sequences were deposited in the GenBank database under the following 
accession numbers: JX308234 (FluA), JX915256 (FluB), and JX448408 (FluC) 
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3.4 Supplement Information for Cloning of Module 4  
The Complete List of the Primers for Module 4 
Part1: the following primers were designed for PCR when DMSO is applied. 
Avul-Mod4-F1: CCGCACCCTCAGCAACCGCC 
Avul-Mod4-R1: CAGCCATGCCGTCCCGCCTTC 
Avul-Mod4-F2: CCCGCACCCTCAGCAACCGC 
Avul-Mod4-R2: AGCCATGCCGTCCCGCCTTC  
Avul-Mod4-F3: CGATTCTGCGTGGGCTGGCT 
Avul-Mod4-R3: TGGATGGCGACGAGCGAGGA 
Avul-Mod4-F4: CCCTCAGCAACCGCCACGAC  
Avul-Mod4-R4: CCTCGGGCAGGGGTCCTCGG 
Avul-Mod4-F5: CCGCTCAATCCCTCGCCTGG 
Avul-Mod4-R5: TCTCCTCGACCTCGCGCAAACGT 
Avul-Mod4-F6: CGCTGGAACGCCGTCTGACC 
Avul-Mod4-R6: CGCTCCTTCTCCTCGACCTCG 
Avul-Mod4-F7: TAAAGCGCCTGGTGTTGGCCTC 
Avul-Mod4-R7: ATCTTGATCACACCGGCCACG 
Avul-Mod4-F8: GTTCACCGCCATGGGTGCCA 
Avul-Mod4-R8: CGTTCGGAGCCGTCAACCCAT 
Avul-Mod4-F9: AGGAGACCAAGCCCCCGAC 
Avul-Mod4-R9: GACTGGCAGGCCATGTGGATG 
Avul-Mod4-F10: CGATCCACCGCCACACCAC 
Avul-Mod4-R10: CAACGACTACGAGGTGGGCCGA 
Avul-Mod4-F11: GCCTGCCCGCTCAATCCCTC 
Avul-Mod4-R11: GAAGAACGCGGGGTCGAACTC 
Avul-Mod4-F12: TCTGCTCGGGGTGGAGGACG 
Avul-Mod4-F13: GCCTCTCTGCTCGGGGTGGA 
Avul-Mod4-R12: CTCTTCGTCAGCCATGCCGTC 
Avul-Mod4-R13: AAGGACCGTTCGGAGCCGTCAAC 
Avul-Mod4-F14: ACGGGTGGCACAGGTGGTCT 
Avul-Mod4-R14: ATCACCCGCTCCTGCGAAGGAC 
Avul-Mod4-F15: CGATGGTGAGTTGGCGGCGT 
Avul-Mod4-R15: GTGGATGGCGACGAGCGAGG 
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Avul-Mod4-F16: GGTGTTCGCCGAGGTGGAGC 
Avul-Mod4-R16: ACGCCGAACGACGACACACC 
Avul-Mod4-F17: GTTCGCCTGGAACGGGGTGG 
Avul-Mod4-R17: CCGACCGACTCCCACAACGC 
Avul-Mod4-F18: GATCCACCGCCACACCACCG 
Avul-Mod4-R18 GACCCCGACCGACTCCCACA 
Avul-Mod4-F19: GATGGTGAGTTGGCGGCGTTGC 
Avul-Mod4-R19: TGCCGTCCCGCCTTCCCTAA 
Avul-Mod4-R20: CCGTTCCCAGTCCACCCCCA 
Avul-Mod4-R21: CCGTTCGGAGCCGTCAACCC 
Avul-Mod4-R22: AGTCCCGATCCCGCCCGTAC 
------------------------------------------------------------------ 
Part2: the following primers were primarily designed for simple cloning as a full module. 
AMod4-F1: AAAAA AGCGTGTCACCGGCAGCGGC 
AMod4-XhoI-R1: TTTTTTCTCGAGCAGGCCCTGGTCGATCAGCGA 
AMod4-F2: AAAAAA TCCAGCGTGTCACCGGCAGCGGC 
AMod4-XhoI-R2: TTTTTTCTCGAGCAGGCCCTGGTCGATCAGCGAGAA 
AMod4-F3: ACCTGCTCCAGCGTGTCACCG 
AMod4-XhoI-R3: TTTTTTCTCGAGCAGGCCCTGGTCGAT (shorter and use HPSF purification when 
synthesized) 
AMod4-F4: CAAGCGGGACGCCCGTTCAAG 
AMod4-XhoI-R4: TTTTTTCTCGAGCAGGCCCTGGTCGATCAG  
AMod4-F5: ATGCCGGAGCCGTTCCTCGTA 
AMod4-XhoI-R5: AAAAAACTCGAGCAGGCCCTGGTCGATCAG 
AMod4-F6: AGGCCACTCGCCACCTCGAT 
AMod4-XhoI-R6: TTATTACTCGAGCAGGCCCTGGTCGATCAG 
AMod4-F7: CCGCCCTCCTTGACCGGGTA 
AMod4-XhoI-R7: TTTTTTCTCGAGCAGGCCCTGGTCGATCAGCGAGAAGAGC 
AMod4-F8: CCTCCCGCCGAGGAGACCAA 
AMod4-XhoI-R8: TTTTTTCTCGAGCAGGCCCTGGTCGATCAGCGAG 
AMod4-XhoI-R8-1: TTTTTTTTTCTCGAGCAGGCCCTGGTCGATCAGCGAG 
AMod4-XhoI-R8-2: TTTTTTTTTTTTCTCGAGCAGGCCCTGGTCGATCAGCGAG 
AMod4-XhoI-R8-3: TTTTTTTTTTTTTTTCTCGAGCAGGCCCTGGTCGATCAGCGAG 
------------------------------------------------------------ 
AMod4-F9: GATTCTGCGTGGGCTGGCTCG 
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AMod4-F10: ATTCTGCGTGGGCTGGCT (like Avul-mod4-F3 but shorter and has lower GC% and use 
HPSF purification) 
AMod4-F11: TTCGGGGTTCACCGCCAT (last 8bp have resemble site within the target sequence) 
AMod4-F12: TCACGGCGGTCTTCCACA (last 8bp only present once in the margin of target 
sequence) 
AMod4-F13: AAAAAACGCTCACGGCGGTCTTCCACA  
AMod4-F14: AAAAAAGATTCTGCGTGGGCTGGCTCG 
AMod4-F15: AAAAAACCTGCTCCAGCGTGTCACCG 
AMod4-F16: TGATCACGGGTGGCACAGGT 
AMod4-F17: GCATCTGCACCAGGCCACTC 
AMod4-F18: CGGGTGGCATGACGAACCAG  
AMod4-F19: CGGAGCCGTTCCTCGTACCT 
AMod4-F20: CTCTGCCCATCAACACCCGCA 
AMod4-F21: CGACGCTGGTGTTCGACCATC 
AMod4-F22: GTGTTCGACCATCCCACGCC 
------------------------------------------------------------------ 
Avul-Mod4-aF1: TCAAGCGTGCTACCGCCGACCT 
Avul-Mod4-aF2: GGGACTACCTCAAGCGTGCTAC 
Avul-Mod4-aF3: CGTGCTACCGCCGACCTTCAG 
Avul-Mod4-aF4: GCGAGGTCGAGGCGAAGGATC 
-------------------------------------------------------------------- 
Avul-Mod4-bF1: TGCGTGGCGACGAGGTGTTC 
Avul-Mod4-bF2: AGGGTGTCGGGTTGTCGCTGGT 
Avul-Mod4-bF3: GGGAGGCGGTGCTGGTGTTC 
Avul-Mod4-bF4: ATCACGGGGTGGGGGAGACG 
Avul-Mod4-bF5: AGGTGTTCGCCGAGGTGGAGCT 
Avul-Mod4-bF6: TGTCGTCGTTCGGCGTCAGC 
Avul-Mod4-bF7: GACTACGCCTCGCACTCCGC 
Avul-Mod4-bR1: ATGCCGTCCCGCCTTCCCTAAG 
Avul-Mod4-bR2: GCAAACGTCGGTTGGCCTGCTG 
Avul-Mod4-bR3: ACCTCGTAGTCGTTGGCGAAGGC 
Avul-Mod4-bR4: TCGGCCCACCTCGTAGTCGTTG 
Avul-Mod4-pF1: CTCGTACCTCTGCCCATCAACAC 
Avul-Mod4-pR1: TTCTCTTCGTCAGCCATGCCGT 
Avul-Mod4-pF2: ATCAACACCCGCACCCTCAG 
Avul-Mod4-pR2: TAAGTCGTCCCGCTGCTGTC 
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Avul-Mod4-pF3: CACACCGGCAAGATCATCCTGAC 
Avul-Mod4-pR3: GGTTTCGAGTTGCTGTGGGAC  
Avul-Mod4-pF4: ATGACGAACCAGTTGTCGGAAC 
Avul-Mod4-pR4: TAAGGGGTTTCGAGTTGCTGTG 
Avul-Mod4-pF5: GACGAACCAGTTGTCGGAACTC 
Avul-Mod4-pR5: TTCCCTAAGGGGTTTCGAGTTG 
Avul-Mod4-pF6: TCCTTGACCTCTGTCGAGTTGC 
Avul-Mod4-pR6: GGATCTCGGTGAAACATTCCTC 
Avul-Mod4-pF7: CCGTTCAAGGATCTCGGTTTC 
Avul-Mod4-pR7: CCTTCCCTAAGGGGTTTCGAGT 
Avul-Mod4-pF8: CAGTTGTCGGAACTCGACCTG 
Avul-Mod4-pR8: CTCTCGATGGACTCCAGAGCA 
Avul-Mod4-pF9: ACCAGTTGTCGGAACTCGACCT 
Avul-Mod4-pR9: GCTGGAGATCCTCGGTCACTC 
Avul-Mod4-pF10: CTCGCCTGGTAAGCAGCATC 
Avul-Mod4-pR10: CGTGGTCACGTACAGGGTCTG 
Avul-Mod4-pF11: CAACTCCTGGACGTCGCTCT 
Avul-Mod4-pR11: AACCTGACCCTGCTCCCAAT 
Avul-Mod4-sF1: ACTGACCTGGAGACGGCTGGTG 
Avul-Mod4-sF2: GACGCCCGTTCAAGGATCTCG 
Avul-Mod4-sF3: CCTGGACGTCGCTCTGACAATGC 
Avul-Mod4-sF4: GGACGCCCGTTCAAGGATCTC 
Avul-Mod4-sR1: GCGAGGAGCTTCTCTTCGTCAGC 
Avul-Mod4-sR2: GTCCTCGGCCCACCTCGTAGTC 
Avul-Mod4-sR3: GCTGGAGATCCTCGGTCACTCG 
Avul-Mod4-sR4: GTAAGTCGTCCCGCTGCTGTCC 
Avul-Mod4-cF1: GTGCTGGTGTCCCTGGTCTGC 
Avul-Mod4-cF2: CATCAACACCCGCACCCTCAG 
Avul-Mod4-cF3: CGTTCCTCGTACCTCTGCCCATC 
Avul-Mod4-cF4: GGAGCCGTTCCTCGTACCTCTGC 
Avul-Mod4-cF5: GAGCTGTTCGCCGATGGTGAG 
Avul-Mod4-cR1: CTCCACGAACTCCTCCAGCACCT 
Avul-Mod4-cR2: CCACGAACTCCTCCAGCACCTG 
Avul-Mod4-cR3: GTTGTCCGCACTCACCTCCAACC 
Avul-Mod4-cR4: CCACCTCGTAGTCGTTGGCGAAG 
Avul-Mod4-cR5: CCTGCTGGAGATCCTCGGTCACT 
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Part3. the following primers were designed for cloning module 4 into two separated half-parts 
DNA, when a MluI site at 3343/3347 [GCGGCCGTGG A CGCG T CATGCCGCCG] of module 4 was 
identified. 
3a. For M4-1f fragments: 
AMod4-HindIII-F1: AAAAAA AAGCTT GGCAAGATCATCCTGACCA 
AMod4-HindIII-F2: AAAAAA AAGCTT CGTTCAAGGATCTCGGTTTC 
AMod4-HindIII-F3: AAAAAA AAGCTT GCGTTCGTGCTCTACTCCTC 
AMod4-HindIII-F4: AAAAAA AAGCTT CAAGATCATCCTGACCATGC 
AMod4-HindIII-F5: AAAAAA AAGCTT TATCGCAGCTTCGACCTGAT 
AMod4-HindIII-F6: AAAAAA AAGCTT CAGCTTCGACCTGATGGATG 
AMod4-HindIII-F7: AAAAAA AAGCTT CGCAGCTTCGACCTGATGGATG 
AMod4-HindIII-F8: AAAAAA AAGCTT CGGCAAGATCATCCTGACCATGC 
(The following were used with HindIII-forward) 
AMod4h-R1: AGAGTCGCCCGTCTCCAGGGT 
AMod4h-R2: AGCTCCCGCAGGATCAGCGA 
AMod4h-R3: CTTGAGCCCCTGGAACGCCG 
AMod4h-R4: GTGGCTCGACACGTCCACCG 
AMod4h-R4: CCTGCTCGGGGTCGGACAGA 
AMod4h-R5: GAGTCGTCGGAGAGTCGTTC 
AMod4h-R6: GAAGGGCAGAGTGATCTTCG 
AMod4h-R7: TCTTCGAGTCGTCGGAGAGT 
AMod4h-R8: CACGTACTCCTCGACACCAC 
AMod4h-R9: GGTACATGCCCAAGGAGTTGA 
AMod4h-R10: CGGGTACATGCCCAAGGAGTTGA 
AMod4h-R11: TTCGAGTCGTCGGAGAGTCGTTC 
3b. For M4-2f fragments: 
(The following were used with XhoI-reverse) 
AMod4h-F1: ACCCATCTCACCGCCACCAA  
AMod4h-F2: TCACATCGGCACGAGCAACG 
AMod4h-F3: GCCCTCCAAACCGCCCTCAC 
AMod4h-F4: CGTTGTGGCTGGGGTCGGTC 
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AMod4h-F5: CCAAACCACCTACACCCAACC 
AMod4h-F6: ACACATCACCCACCACTTCA 
AMod4h-F7: CAACGCACAAGACATCCAACA 
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CHAPTER 4.  
EXAMING SUSTRATE SELECTIVITY OF DOMAINS IN FLUVIRUCIN B1 PKS SYSTEM AND 
BIOINFORMATIC ANALYSIS OF KETOSYNTHASE ON SUBSTRATE SPECIFICITY 
4.1 Introduction 
In the past two decades, the effort of engineering polyketide synthase has focused on the 
domain manipulation of the enzyme systems, but the substrate specificities of critical domains 
obstruct the engineering effort and the development of producing “un-natural” natural product. 
A key step within the megasynthase is the substrate transferring of the polyketide intermediate 
between an upstream ACP and a downstream KS domain (Figure 24). This process is controlled 
Figure 24. Schematic diagram of intermodular transfer in modular polyketide synthases.  
A polyketide intermediate is passed from an upstream ACP to a downstream KS via the 
phosphopantetheine arm of holo-ACP.  Often the substrate selectivity of the acceptor 
KS domain determines the efficiency of this process and controls the flow of 
intermediates down the assembly line.  KS = ketosynthase, ACP = acyl carrier protein, AT 
= acyltransferase, DH = dehydratase, ER = enoyl reductase, KR = ketoreductase. 
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either via precise regulation of kinetics where ACP to KS transfer is slow compared to KR, DH, and 
ER activity, or strict inherent substrate selectivity of the KS domain.  For kinetically-controlled 
transfer, changes in substrate functionality should not impede the overall production of 
engineered products.  Conversely, those KS domains that exhibit tight substrate selectivities 
may detrimentally impact product yields through greatly reduced kinetics and off-target, shunt 
product formation.  In these cases, a comprehensive understanding of substrate tolerance and 
the ability to alternative selectivities is required for polyketide diversification.  Recent insights 
from KS structure determination have provided clues to potential substrate recognition motifs 
within the KS active site pocket.  However, these principles remain largely untested and thorough 
analysis is needed to determine whether KS selectivities can be changed or broadened by proper 
mutation of residues within these motifs.  
Early determinations of KS substrate selectivity relied heavily on radiolabeling of 
elongation products or, less commonly, the substrates themselves. 1 - 4  Small molecules were 
generally delivered to the KS active site via a compatible ACP or as an N-acetylcysteimine (SNAc) 
thioester, a more synthetically accessible mimic of the phosphopantetheine (Ppant) arm of holo-
ACPs. Subsequent addition of radiolabeled extender units resulted in a single elongation event 
with the KS-bound substrate.  The amount of labeled product excised from the protein provided 
an indirect measure of KS loading with each substrate.  While very sensitive, the combination of 
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high reagent cost and limited substrate availability has severely restricted the use of this method 
for medium and high-throughput applications.   
More recently, a number of groups have developed mass spectrometry-based techniques 
for examining KS active site acylation.5-7 Many of these strategies utilize tandem proteolysis/LC-
MS to tease out differences in loading propensities for various substrates.  Despite the many 
advantages compared to radiolabeling, MS-based methods still suffer from a number of important 
shortcomings.  Firstly, the extremely large size of intact PKS modules generally prohibits their use 
in these analyses.  Smaller subunits such as KS-AT didomains are often employed as substitutes 
for the full module and currently it is unclear what, if any, effect this has on substrate selectivity.  
In addition, the influence of various substrates on ionization potentials, especially when 
proteolysis is employed prior to analysis, has not been fully explored and may significantly impact 
data interpretation and reproducibility.  Finally, when particular hydrophobic groups (e.g. octyl, 
napththyl, cyclohexyl) are utilized as a substantial part of a given substrate, loss of signal for 
proteolysis fragments associated with KS domains is often observed, likely due to solubility issues. 
In addition, our lab has developed a fluorescence transfer assay for facile determination 
of KS selectivities.8 The degree of KS acylation for a given SNAc substrate can be assayed by 
introducing a fluorescent ACP, prepared from Ppant acylation with a clickable β-lactam, after 
incubation of KS and substrate and monitoring ACP to KS fluorescence transfer via gel 
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electrophoresis.  The amount of fluorescence transfer indicates to what extent the SNAc 
compound is accepted by the KS domain (Figure 25).  High KS-loading blocks subsequent 
fluorescence transfer from ACP, and thus produces little to no fluorescent signal in the gel. 
Alternatively, insufficient KS-acylation with a given SNAc compound leaves most KS active sites 
free to accept the fluorescent substrate from ACP resulting in a bright band.  This technique 
provides a direct measure of KS selectivity while circumventing the limitations of radiolabeling 
Figure 25. Schematic diagram of a mechanism-based, fluorescence transfer assay for KS-
selectivity.  A given KS domain is incubated with acyl-SNAc followed by addition of fluorescently 
labeled ACP.  The amount of fluorescence transferred from the ACP to the KS active site 
provides a direct readout of the substrate tolerance for each acyl-SNAc examined. KS = 
ketosynthase, ACP = acyl carrier protein, AT = acyltransferase, SNAc = N-acetylcysteamine. 
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and mass spectrometry methods described above.  Most importantly, the use of mechanism-
based fluorescence transfer from acyl-ACPs ensures that any fluorescence observed on the 
acceptor module results solely from the KS active site and not from competing, nucleophilic 
surface residues within the complex protein system.  
As we unearthed a new PKS system, fluvirucin B1 synthase, an ideal system for engineering 
un-natural polyketides, we were eager to figure out the substrate specificity within the domains 
of fluvirucin B1 PKS in order to overcome the engineering hurdle that we describe above. Herein, 
we described our finding for FluAT selectivity and FluKS specificity, and also provided our 
bioinformatic analysis of FluKS for future engineering purposes (see section 5.3.1). 
4.2 Results and Discussions 
4.2.1 Cloning and Protein Expression of KSATs and ACPs 
To determine the selectivities of the domains in this assembly line, appropriate primers 
were designed for the cloning of all KS-AT didomains within fluvirucin B1 PKS. However, even 
though all five KSATs were cloned out without any difficulties, only KSAT of modules 1, 3 and 5 
were successfully expressed in E. coli BL21 strain. On the contrary, ACPs of all the five modules 
were successfully cloned and expressed in E. coli BAP1 strain in order to harvest the fully 
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functional ACPs purified with the Ppant group. In addition, the terminal TE domain were also 
cloned and overexpressed in BL21 (Figure 26). 
4.2.2 Examine the AT Selectivities.  
To examine the domain selectivities, we began synthesizing substrate analogs to probe 
FluATs. We are convinced that not only the information could be useful to confirm the result from 
our bioinformatic analysis, but also we could establish the methodology we deployed for other 
domains as well in terms of using LC-MS. 
As we alluded in chapter 2, using the SEARCHPKS program developed by Mohanty and co-
workers9, modules 2 and 4 showed high sequence similarity with malonyl-specific AT domains, 
while module 3 was predicted to utilize methylmalonyl-CoA. Modules 1 and 5 returned a single 
Figure 26. SDS PAGE analysis of fluvirucin B1 PKS domains overexpressed in E. coli following Ni-
NTA affinity purification. Lanes are marked with corresponding protein. Molecular weights are 
indicated for each gel. (A) Flu-KSAT didomains (B) Flu ACP domains (C) Flu TE domain. 
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hit for ethylmalonate specificity amidst several methylmalonylspecific AT domains. To 
experimentally verify the putative AT selectivities for modules 1, 3, and 5, ketosynthase-
acyltransferase (KSAT) didomains were cloned from these modules along with the corresponding 
ACP domains. Each KSAT didomain was mixed with ACP from the same module followed by 
introduction of either malonyl-, methylmalonyl-, or ethylmalonyl-N-acetylcysteamine (SNAc) 
Figure 27. Schematic diagram of and observed results for the AT substrate selectivity studies 
of modules 1, 3, and 5. Red checks indicate that the substrate shown on the left is transferred 
from the indicated AT to the ACP domain, whereas a black X indicates that no substrate
transfer was observed. See Supporng Informaon for raw LC−MS data. FluATX = fluvirucin 
AT domain from module X. 
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thioesters.  Following 30 min of incubation with each substrate, samples were trypsinized, and 
the extent of AT to ACP transfer for each extender unit was analyzed by LC−MS (Figure 27). 
Gratifyingly, experimentally determined AT selectivities for modules 1, 3, and 5 were consistent 
with those suggested by sequence homology. It is important to note that no direct acylation of 
ACP was observed with any of the extender units, indicating that AT to ACP transfer is the sole 
mechanism for formation of the acylated ACP (data not shown). 
4.2.3 FluKS Substrate Selectivity 
As we summarized before, the capability of KS domain accepting different substrates 
could potentially increase product yields in polyketide engineering. On the way in characterizing 
our unique fluvirucin B1 PKS, one of our objectives is to test the tolerance of KSs by applying the 
technique we developed and described above. We believed that gaining the information of the 
KS selectivity would provide the reference of altered β-functionalities and insight for better 
polyketide engineering. Based on our current bioinformatic analysis and prediction, FluKSs only 
have two different kind preferences of β-substituents: one is a methylene and the other a β-
hydroxyl substituent, we will focus on Flu KS3 which only accepts a β-hydroxy acyl group of all the 
KS domains. 
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To examine the selectivity in FluKS3 for the hydroxyl group stereo-configuration and 
provide further evidence connecting this PKS with fluvirucin B1 production, tandem 
proteolysis/LC−MS was again employed. SNAc thioesters of both enantiomers of 3-
hydroxybutyrate were prepared and introduced separately to KSAT3. Following 1 h of incubation, 
samples were trypsinized, and KS-acylaon was observed via LC−MS analysis. As predicted from 
the fluvirucin B1 structure, only the (S)-3-hydroxybutyryl-SNAc compound, which places the 
hydroxyl group in the same three-dimensional orientation as the ring hydroxyl of the final 
product, was accepted by the module 3 KS domain (Figure 28). Very little to no KS-acylation with 
the (R)-isomer was observed.  
Figure 28. LC−MS data for module 3 KS-acylation with (R)-3-hydroxybutyryl-SNAc (top) and (S)-
3-hydroxybutyryl-SNAc (bottom). Only the (S)-isomer is accepted by module 3 KS as is expected 
from the fluvirucin B1 structure. Peaks are labeled with the corresponding acylated or 
unacylated KSAT3 didomain. All peaks are m/z = +2. 
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The mechanism based fluorescence transfer assay that was developed in our lab was also 
used to examine the stereochemical preference of Flu KS3. The fluorescent ACP was prepared by 
incubating holo Flu-ACP3 with N-propargyloxycarbonyl-β-lactam for an hour. The acylated ACP 
was then “clicked” with rhodamine azide. The KSAT3 was preloaded with the substrates for an 
hour followed by addition of the fluorescent ACP for 30 minutes and SDS PAGE analysis of each 
reaction. The bright KSAT3 bands observed for the (R) - stereoisomer indicates that there was 
little to no KS acylation. The weak fluorescent band observed in the (S) - stereoisomer lane is an 
indication of efficient KS acylation and confirms the earlier LC-MS results obtained (Figure 29). 
Subsequently, we prepared a small panel (Figure 30) of SNAc thioesters for a preliminary 
test on FluKS3. They incorporate different variations of hydroxyl, enoyl and fully reduced carbon 
at the beta position. This panel is a good starting point to investigate the preferences of KS for 
Figure 29. Mechanism based fluorescence transfer assay for Flu KSAT 3 substrate specificity 
towards (R)-and (S)-3-hydroxy butyryl SNAc 
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variation of functionalities at the 
beta position and be used further 
as a framework for testing the 
other four KSs in this PKS system. 
By following the same procedure 
for LC-MS methodology, we found 
that FluKS3 prefer not only the (S)-
isomer but also the β-keto thioester probe, and that FluKS3 slightly interacts with the β-
methlyene analog but does not accept any other substrates (data not shown). In sum, we suggest 
these preliminary experiments will provide some insight into the extent and contrasts of tolerance 
exhibited within other KSs.  
4.3 Experimental Procedures 
4.3.1 Cloning of KSAT and ACP Domains of Fluvirucin B1 PKS  
The DNA sequence encoding Flu-KSAT1 was amplified from pTL-A01 by the PCR protocol 
described for pre-module 2. Flu-KSAT1 was constructed as an NheI-EcoRI fragment by using 
following primers, pTL-KSAT1-F: TTTTTTGCTAGCGAGCCCATCGCGATCGTC and pTL-KSAT1-R: 
AAAAAAGAATTCTGGTCCACGGCGGCCTGG. This NheI-EcoRI fragment was cloned into the pET21b 
Figure 30. A panel of substrate analogs for KS selectivity 
 81 
expression vector to yield plasmid pTL-KSAT1. The DNA sequence encoding Flu-KSAT3, Flu-KSAT5 
and Flu-ACP1, Flu-ACP3, Flu-ACP5 were cloned similarly by the corresonding templates the 
corresponding primers as follows, pTL-KSAT2-F: TTTTTTGCTAGCGAGCCGATCGCGATCGTG 
pTL-KSAT2-R: AAAAAAGAATTCAGGGAGGACAGGGCGGGAAG 
pTL-KSAT3-F1: TTTTTTGCTAGCATGGCCACTGACGACAAG, 
pTL-KSAT3-R1: AAAAAAGAATTCGGATCCACCCGGGTCAGG; 
pTL-KSAT4-F: TTTTTTGCTAGCATCGGGGAGCCGATCGCGATC, 
pTL-KSAT4-R: AAAAAAGAATTCTGGTCCGCGGGGGCCTGGC; 
pTL-KSAT5-F1: TTTTTTGCTAGCATGGCTGACGAAGAGAAG, 
pTL-KSAT5-R2: AAAAAAGAATTCTGATCCACCCGAGCCTG; 
pTL-ACP1-F: TTTTTTGCTAGCCTGACCGGACTACCGGCG, 
pTL-ACP1-R: AAAAAAGAATTCGTGACACGCTGGAGCAG; 
pTL-ACP2-F: TTTTTTGCTAGCCTCGCGGAGCTGCCGCCGGCC, 
pTL-ACP2-R: AAAAAAGAATTCGTGAGCCTGTCCTGGACGAAC; 
pTL-ACP3-F:TTTTTTGCTAGCCTGACCGGCCTGCCCGCG,  
pTL-ACP3-R: AAAAAAGAATTCGTGACACGCTGGAGCAG;  
pTL-ACP4-F: TTTTTTGCTAGCCTGGCCGGGCTGCCCCCG 
pTL-ACP4-R: AAAAAAGAATTCAGGAGCTGGCTCCCCATGTA 
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pTL-ACP5-F: TTTTTTGCTAGCCTGGCCGGGCTGTCG,  
pTL-ACP5-R:AAAAAAGAATTCGCGATCTCCTCCGCCAG 
The resulting plasmids for Flu-KSATs (pTL-KSAT1 to 5) were transformed into BL21(DE3). 
The plasmids constructed for Flu-ACPs (pTL-ACP1 to 5) were introduced into BAP1. 
4.3.2 General Method for Preparation of All N-Acetylcysteamine (SNAc) Thioester Derivatives  
To a solution of triethylamine (2.80 mmol) in dichloromethane (10 mL) was added the 
appropriate acid (1.40 mmol), (3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.40 
mmol), 1-hydroxybenzotriazole (HOBt) (1.40 mmol) and N-acetylcysteamine (SNAc) (1.35 mmol) 
under argon. The reaction mixture was stirred overnight. The organic layer was washed with 
saturated NaHCO3 solution, 0.1 N HCl solution and brine. It was then dried over anhydrous sodium 
sulfate, concentrated under vacuum, and purified by flash column to provide the final product in 
pure form. 
Butyroyl SNAc  
Using butyric acid, the general procedure was followed  
1H NMR (400 MHz, CDCl3) δ ppm 0.92-0.96(t, J=, 3H), 1.67-1.69(m, 2H), 1.95(s, 3H), 2.52-
2.56(t,2H),2.99-3.00(t, 2H), 3.40-3.42(q, 2H), 6.12(s, 1H).  
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13C NMR (400 MHz, CDCl3) δ ppm 11.54, 17.17, 21.27, 26.55, 37.64, 44.12, 168.64, 197.97.  
IR: ν 3291.13, 2967.08, 1651.12, 1547.47, 1436.23, 1370.50,1284.55, 1112.64, 988.76, 905.33, 
723.31 cm−1  
LC-MS [M+H]+ = 190.0. 
Trans-2-butenoyl SNAc  
Using crotonic acid, the general procedure was followed.  
1H NMR (400 MHz, CDCl3) δ 1.86 (dd, 3 H), 1.93 (s, 3 H), 3.05 (t, 2 H), 3.44 (dt, 2 H), 6.11 (dq, 1H), 
6.21 (s, 1 H), 6.90 (dq, 1 H);  
13C NMR (400 MHz, CDCl3) δ 17.9, 23.1, 28.1, 39.8; 129.8, 141.7, 170.3;  
LC-MS [M+H] 188.2  
(R)-3-hydroxy butyroyl SNAc  
Using (R)-hydroxy butyric acid, general procedure was followed  
1H NMR (400 MHz, CH3Cl-d) δ ppm 1.33 (3 H, d, J=6.82 Hz), 1.98 (3 H, s), 2.65 - 2.76 (2 H, m), 2.78 
- 2.82 (1 H, d), 3.04 - 3.10 (2 H, t), 3.27 - 3.31 (1 H, m), 3.42-3.46(3H, q), 6.36 (1 H, br. s.)  
13C NMR (400 MHz, CH3Cl -d) δ ppm 19.76, 21.35, 26.95, 28.50, 34.57, 37.48, 49.19, 168.60, 195.73  
LC-MS [M+H] for C8H15NO3S calcd 206.1 found 206.1  
(S)-3-hydroxy butyroyl SNAc  
Using (S)-hydroxy butyric acid, general procedure was followed.  
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1H NMR (400 MHz, CH3Cl-d) δ ppm 1.33 (3 H, d, J=6.82 Hz), 1.98 (3 H, s), 2.65 - 2.76 (2 H, m), 2.78 
- 2.82 (1 H, d), 3.04 - 3.10 (2 H, t), 3.27 - 3.31 (1 H, m), 3.42-3.46(3H, q), 6.36 (1 H, br. s.)  
13C NMR (101 MHz, CH3Cl -d) δ ppm 19.76, 21.35, 26.95, 28.50, 34.57, 37.48, 49.19, 168.60, 195.73  
LRMS [M+H] for C8H15NO3S calcd 206.1 found 206.1 
β-keto butyroyl SNAc  
To a solution of meldrum acid (10mmol) in dichloromethane at 0oC was added pyridine 
(21mmol). Acetyl chloride (12mmol) was added dropwise to the mixture, with the solution turning 
deep red. The reaction was stirred for an hour at 0oC and then warmed to room temperature 
overnight. Mixture was washed 3X with 0.1M HCl, dred with sodium sulfate and concentrated to 
yield the acetylated meldrum acid as a dark orange solid in 84% yield. 8mmol of this acetylated 
meldrum acid and 7.7mmol of N-acetylated cysteamine (SNAc) were refluxed in toluene for 
5hours. After the mixture was cooled to room temperature, it was concentrated to yield titled 
compound in 78% yield. 
4.3.3 Synthesis of malonyl and substituted malonyl SNAc thioesters  
These syntheses we carried out using established procedures25. A general outline follows: 
To a solution of appropriate malonic or substituted malonic acid (1eq) in dry THF (5mL), was added 
pyridine (2.2eq) and t-butanol (1.8eq). The solution was cooled to 0°C. Methanesulfonyl chloride 
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(1.05eq) was then added dropwise over a 10 minute period. The reaction mixture was warmed to 
room temperature and stirred for 3 hours. The mixture was filtered and the resulting filtrate 
diluted with water. The pH was adjusted to ~12 and washed 3X with dichloromethane. The 
aqueous layer was acidified (pH ~2), extracted 3X with dichloromethane and dried with sodium 
sulfate. The product was then coupled to SNAc via EDC coupling. In an RB flask, the acid (1.1eq) 
was dissolved in dichloromethane. EDCI (1.2eq), DMAP (0.02eq) and SNAc (1eq) were then added 
and reaction stirred at room temperature overnight. The mixture was diluted with water and 
dichloromethane. The organic layer was washed with NH4Cl, NaHCO3, and brine, and then dried 
with Na2SO4. Concentration in vacuo yielded the expected product. The product was dissolved in 
TFA at 0°C. After stirring at 0°C for 24 hours, TFA was evaporated. The product was diluted with 
diethyl ether and concentrated. This was repeated three times. The crude product was purified 
by chromatography to yield the titled compound.  
Malonyl SNAc thioester (pale white solid) (70% yield)  
1H NMR (400 MHz, DMSO-d6) δ ppm 1.79 (br. s., 3 H), 2.95 (br. s., 2 H), 3.18 (br. s., 2 H), 3.65 (br. 
s., 2 H), 8.06 (br. s., 1 H)  
13C NMR (400 MHz, DMSO-d6) δ ppm 21.04, 27.06, 36.57, 48.21, 165.97, 167.91, 190.24  
LRMS [M+H] for C7H11NO4S calcd 206.0 found 206.1  
Methyl Malonyl SNAc thioester (pale white solid) (63% yield)  
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1H NMR (400 MHz, CH3Cl -d) δ ppm 1.44 (3 H, d, J=7.07 Hz), 1.99 (3 H, s), 3.06-3.17 (2 H, m), 3.40 
- 3.52 (2 H, m), 3.63 - 3.77 (1 H, m), 6.71 (1 H, t, J=5.56 Hz), 10.35 (1 H, br. s.)  
13C NMR (400 MHz, CHLOROFORM-d) ppm 12.13, 20.74, 26.59, 37.64, 52.07, 170.24, 170.59, 
194.96  
LRMS [M+H] for C8H13NO4S calcd 220.1 found 220.1  
Ethyl malonyl SNAc thioester (pale yellow solid) (51% yield)  
1H NMR (400 MHz, CH3Cl -d) δ ppm 1.01 - 1.06 (2 H, m), 2.01 (3 H, s), 3.05 (1 H, dd, J=13.26, 6.69 
Hz), 3.11 - 3.22 (1 H, m), 3.37 (1 H, t, J=7.20 Hz), 3.48 ( 2H, q, J=5.89 Hz), 3.56 (1 H, t, J=7.45 Hz), 
6.59 (1H, br. s.), 11.53 (1H, br. s.)  
13C NMR (101 MHz, CH3Cl -d) δ ppm 9.83, 20.63, 20.98, 26.62, 37.73, 51.02, 59.44, 170.96, 172.31, 
194.21  
LRMS [M+H] for C9H15NO4S calcd 234.1 found 234.1 
4.3.4 ACP Acylation by AT  
To a mixture of ACP (50 μM) and KS-AT (2 μM) in 100mM pH 7.0 phosphate buffer (50 μL 
total volume) containing 2.5 mM TCEP at 4°C was added appropriate SNAc thioester substrate 
(500 μM) . The mixture was incubated 4°C for 30 min to achieve AT assisted acylation of the ACP. 
Sequence grade modified trypsin was added to prepare samples with final ration trypsin:ACP to 
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be 1:10 (w/w). The mixture was incubated for 60 min at 37°C. Digestion was quenched by addition 
of equal volume of 10% formic acid. Digests were stored at -80°C until analysis. 
4.3.5 KSAT3 Loading  
To a mixture of Flu-KSAT3 (25 μM) in 100 mM pH 7.0 phosphate buffer (50 μL total 
volume) containing 2.5 mM TCEP at 4°C was added appropriate SNAc thioester substrate (5mM). 
The mixture was incubated 4°C for 60 min to achieve KS acylation. Sequence grade modified 
trypsin was added to prepare samples with final ratio trypsin:ACP to be 1:10 (w/w). The mixture 
was incubated for 60 min at 37°C. Digestion was quenched by addition of equal volume of 10% 
formic acid. Digests were stored at -80°C until analysis. 
4.3.6 Fluorescence Transfer Assay  
Unless otherwise stated, phosphate buffer refers to 100 mM, pH 7.0 phosphate. Flu-ACP3 
(25 μM total protein) was equilibrated at ambient temperature for 15 min in phosphate buffer 
containing 2.5 mM TCEP. Poc β-lactam (10× with respect to total ACP concentration) was added 
and the mixture was equilibrated at ambient temperature for 45 min. Rhodamine Azide (2× with 
respect to Poc β-lactam), sodium ascorbate (1 mM), and copper (II) sulfate (1 mM) were added to 
ACP samples which had been labeled with Poc β-lactam. The reaction was performed at ambient 
temperature for 45 min. To remove excess Poc β-lactam and Rhodamine Azide, the mixture was 
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loaded into a 3 kDa NMW concentrator and the volume reduced to 100 μL by spinning in a 
centrifuge cooled to 4 °C. The mixture was diluted to 500 μL with phosphate buffer, and then 
concentrated to 100 μL again. This process was repeated a total of 5 times. Protein was removed 
from the concentrator by inverting it and spinning. For transfer of the fluorescent product, [Flu-
KSAT3] was pre-treated with respective SNAc (2.5 mM) derivatives for 1 h. This mixture was 
introduced to filtered acyl-ACP3 and incubated for 30 min. The [Flu-KSAT3] control was executed 
under the same acylation and click conditions as in other samples but without the SNAc derivative 
and therefore represents full acyl transfer. 
4.3.7 Chromophore Attachment  
The reaction was carried out at 25 μL, final concentrations reported. Rhodamine Azide, 
(2× with respect to Poc β-lactam), sodium ascorbate (1 mM), and copper (II) sulfate (1 mM) were 
added to ACP samples which had been labeled with Poc β-lactam. The reaction was performed at 
ambient temperature for 45 min.  
4.3.8 Gel Assay  
Labeled samples were diluted to 20 μL with gel-loading buffer. Proteins were separated 
using a 4–20% gradient HEPES-PAGE gel (100 V, 50 mA, 70 min). Gels were developed in 10% 
acetic acid to visualize Rhodamine Azide. Labeled proteins were imaged on a UV-transilluminator. 
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Total protein was stained using Coomassie stain.trypsin was added to prepare samples with final 
ration trypsin:ACP to be 1:10 (w/w). The mixture was incubated for 60 min at 37°C. Digestion was 
quenched by addition of equal volume of 10% formic acid. Digests were stored at -80°C until 
analysis.  
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CHAPTER 5.  
SUMMARY AND FUTURE DIRECTIONS 
5.1 Discussion 
Fluvirucin B1 is a relatively simple natural product stemming from a rather complex set of 
biosynthetic transformations. Despite the diminutive size of the PKS responsible for its production 
in A. vulgaris, each round of elongation and subsequent β-carbon tailoring requires extensive 
manipulation of functionality. Four of the five putative extender modules bear the full compliment 
of tailoring domains, meaning that at each of these positions within the assembly, keto-, hydroxyl-
, and olefin-containing intermediates are generated enroute to the fully saturated product, similar 
to mammalian fatty acid synthase. We have hypothesized that this type of module composition 
will afford the highest engineering potential as product diversification can be achieved without 
the need for incorporation of heterologous domains. In other words, one can potentially access 
each of the aforementioned functionalities by simple active site mutagenesis of KR, DH, and ER 
domains leaving the highly evolved protein−protein communication and recognition interfaces in 
their native states. This is in stark contrast to more popular assemblies such as 6-
deoxyerythronolide B synthase (DEBS), where nearly all of the extender modules contain, at most, 
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a KR domain, where only ketone functionalities are accessible via similar active site mutagenesis 
strategies.1 For this reason, we were eager to uncover the biosynthetic origins of fluvirucin B1.  
As predicted, the fluvirucin B1 polyketide synthase consists of 5 extender modules flanked 
by an N-terminal loading ACP and C-terminal TE domain. All but one of the extender modules 
contains a KR, DH, and ER domain in addition to the required KS, AT, and ACP leading to the 
relatively un-functionalized nature of the macrolactam product. On the basis of this arrangement 
of composition of modules, β-alanine is expected to serve as the starter unit for fluvirucin B1 
biosynthesis. As strong evidence for this hypothesis, fluI, which putatively encodes for a PLP-
dependent decarboxylase, displays high homology with both vinO from the vicenistatin PKS 
cluster and azicN from the azicemicin PKS cluster.2,3 The former is responsible for decarboxylation 
of 3-methylaspartate, while the latter decarboxylates aspartic acid itself, leading to 3-methyl-β-
alanine and β-alanine, respectively. While further studies are needed to confirm the starter unit 
identity for fluvirucin B1 biosynthesis, this data strongly suggests a role for β-alanine in the early 
stages of macrolactam construction.  
As alluded to above, thorough analysis of the protein sequences for each module reveals 
an intriguing trend with implications as to the evolutionary origins of these PKS components. 
Pairwise alignments between fluvirucin B1 PKS modules 1, 3, and 5 yield protein sequence 
identities ranging from 75% to 81% (Table 7).  
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Similarly, modules 2 and 4 show 94% sequence identity. When analogous alignments are 
executed between these two groups (e.g., module 1 vs module 2), more typical identities ranging 
from 60% to 64% are observed. By comparison, sequence identities between modules from the 
well characterized DEBS assembly as well as between DEBS modules and fluvirucin PKS modules 
fall in the more modest 40−60% range (Table 8). The similarities between fluvirucin B1 synthase 
modules might suggest independent ancestry for modules 1, 3, and 5 versus 2 and 4. It is 
important to note that the remarkable sequence identities observed within these two groups 
Table 7. Sequence comparison results for Flu modules and DEBS module 4 
Sequence 
comparison 
 
(Identities/ 
Similarities) 
 
 
FluMod1 
 
FluMod2 
 
FluMod3 
 
FluMod4 
 
FluMod5 
 
DEBS 
Mod4 
FluMod1 100%/100% 61%/72% 81%/86% 60%/70% 80%/86% 49%/61% 
FluMod2 61%/72% 100%/100% 64%/75% 95%/96% 64%/75% 58%/72% 
FluMod3 81%/86% 64%/75% 100%/100% 63%/73% 74%/82% 50%/63% 
FluMod4 60%/70% 94%/96% 63%/73% 100%/100% 60%/70% 41%/56% 
FluMod5 80%/86% 64%/75% 75%/82% 60%/70% 100%/100% 49%/62% 
*All sequence comparison done by BLAST of NCBI website. All modules listed in the column are 
used as query, and the modules listed in the row are used as subject. 
**In cases where the compared modules are of dramatically different sizes (i.e Flu Mod 1 vs. Flu 
Mod2) identities are related only to the KS-AT regions (regions of max identity) of the modules. 
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occur despite the fact that each module both accepts and processes appreciably different 
polyketide intermediates. 
Another interesting aspect of the fluvirucin B1 synthase involves the TE domain. Most 
macrocycle-forming thioesterases bear a conserved serine residue charged with accepting the 
fully mature, linear polyketide intermediate from an immediately upstream ACP followed by 
cyclization and product release. 
The fluvirucin B1 TE domain instead uses a cysteine active site for this task. This type of 
serine to cysteine substitution has been observed in other PKS systems, prompting speculation as 
Table 8. Sequence Comparison Results for DEBS Modules 
Sequence 
comparison 
(Identities/ 
Similarities) 
 
DEBS 
Mod1 
 
DEBS 
Mod2 
 
DEBS 
Mod3 
 
DEBS 
Mod4 
 
DEBS 
Mod5 
 
DEBS 
Mod6 
DEBS 
Mod1 
100%/100% 49%/60% 48%/61% 56%/68% 49%/61% 59%/68% 
DEBS 
Mod2 
(49%/60%) 100%/100% 48%/59% 52%/64% 50%/61% 49%/61% 
DEBS 
Mod3 
(48%/61%) (48%/59%) 100%/100% 56%/69% 48%/62% 51%/64% 
DEBS 
Mod4 
(56%/68%) (52%/64%) (56%/69%) 100%/100% 57%/68% (52%/64%) 
DEBS 
Mod5 
(49%/61%) (50%/61%) (48%/62%) 57%/69% 100%/100% (50%/61%) 
DEBS 
Mod6 
(59%/68%) (49%/61%) (51%/64%), 52%/64% 50%/61% 100%/100% 
*Comparison results in parentheses are results from reverse query/subject pairs. 
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to possible divergent evolutionary origins between these two active site arrangements. 4 - 6 
Although beyond the scope of this thesis, this somewhat unique feature of the fluvirucin B1 
synthase should provide additional insights into any kinetic consequences of this switch and thus 
warrants further study. 
5.2 Conclusions  
In summary, we have identified and characterized the putative PKS genes associated with 
fluvirucin B1 aglycone biosynthesis in A. vulgaris. The number and composition of modules as well 
as predicted AT specificities are consistent with the fluvirucin B1 structure. The abundance of 
tailoring domains within the assembly is expected to provide increased engineering potential, 
through straightforward active site mutagenesis. Reconstitution of biosynthesis in a more 
workable host will greatly facilitate these studies and efforts to do so are currently underway in 
our laboratory.  
5.3 Future Directions 
5.3.1 Native Ketosynthase Selectivities in the Fluvirucin PKS  
As alluded to above, our lab has recently developed a mechanism-based fluorescence 
transfer assay for examining KS substrate tolerance (Figure 25, chapter 4).  This method stems 
from previous work using b-lactones and b-lactams as site-specific, electrophilic partners for the 
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Ppant thiol of holo-ACPs.7 - 8  The thioester-ACP resulting from incubation of holo-ACP with a 
propargyloxycarbonyl (Poc)-activated b-lactam was shown to be competitive with traditional 
SNAc thioesters for KS acylation.  Based on these results, it occurred to us that fluorescent 
thioester-ACPs, derived from an alkyne-bearing β-lactam, coupled with acyl-SNAc compounds, 
could provide a straightforward means of examining KS selectivity in whole PKS modules.  
We expect that substrate recognition in KS domains arises primarily from functionality 
near the thioester bond.  Mutational inactivation of KR, DH, and ER domains will afford polyketide 
intermediates with modification at the β-position and thus, this position is the most logical place 
to begin our analysis of substrate recognition.  A panel of SNAc thioesters bearing ketone, 
hydroxyl, olefin, and methylene β-functionalities along with the appropriate hydrogen, methyl, 
and ethyl α-functionalities will be prepared via established methods (Error! Reference source not 
found.). 9   An added benefit of this analysis is that hydroxyl-group stereoselectivities, not 
immediately obvious from the products accepted by modules 2, 4, and 5, will be established for 
future studies utilizing the full fluvirucin PKS.  KS domains from modules 2, 3, 4, and 5 will be 
incubated with SNAc compounds containing each β-functionality and the appropriate α-
functionality, as determined by the immediately upstream AT domain, to establish a substrate 
scope for each.  In the case of inconclusive or irregular observations in the data, traditional LC-MS 
techniques will be used for further confirmation. 
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 From these data, we expect two principal outcomes: 1) KS-domains utilizing purely 
kinetic-control for transfer of the proper intermediate will show little to no selection for a 
particular substrate and, 2) those evolved to only accept a certain substrate will exhibit the 
opposite response to non-native functionality.  Domains that fall into the first category will require 
no alteration and can be used directly for fluvirucin analog production described in section 5.3.3.  
Conversely, for situations where strict substrate selectivities or a combination of both outcomes 
is observed, we will attempt to alter or broaden the substrate scope using targeted mutagenesis 
of residues located in a variable region of the KS active site pocket as detailed in section 5.3.2. 
Figure 31. Panel of SNAc thioesters for determination of KS substrate selectivities in the 
fluvirucin PKS. 
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5.3.2 Altered Ketosynthase Selectivities via Mutation of Active Site Pocket Residues 
Recent crystallographic data for the KS domains of DEBS modules 3 and 5 has provided 
new insights into substrate recognition interfaces surrounding the active site.10  Most of the deep 
KS active site pocket is highly conserved among modular PKSs.  However, as Khosla and coworkers 
observed upon modeling a triketide and pentaketide substrate into the active site of DEBS module 
3 and 5 KS domains, respectively, there exists a small variable region within the pocket that may 
allow the KS to distinguish certain substrate functionalities and sizes (Figure 32. Crystal structure 
of the DEBS module 3 KS 
active site pocket (PDB: 
2QO3).  Active site 
cysteine indicated by a 
green sphere.  The four 
loop residues thought to 
play a role in substrate 
recognition are labeled 
accordingly.  ).   This 
hypothesis is yet untested 
Figure 32. Crystal structure of the DEBS module 3 KS active site 
pocket (PDB: 2QO3).  Active site cysteine indicated by a green sphere.  
The four loop residues thought to play a role in substrate recognition 
are labeled accordingly.   
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and the fluvirucin PKS KS domains exhibiting strict substrate selectivities from section 5.3.1 will 
offer the ideal platform for experimental investigation of the model.  
Motivated by this 
observation, we were 
interested in whether any 
distinct sequence patterns 
could be detected within this 
region that might lead to 
selectivity for each common 
polyketide β -functionality.  
Separate alignments were 
executed for KS domains 
falling into one of four 
categories: those that 
natively accept an 
intermediate bearing a 1) 
ketone, 2) hydroxyl, 3) olefin 
or, 4) methylene at the β-
Figure 33. Consensus sequences for each of the four KS active 
site pocket residues of interest (see Figure 32. Crystal structure 
of the DEBS module 3 KS active site pocket (PDB: 2QO3).  Active 
site cysteine indicated by a green sphere.  The four loop residues 
thought to play a role in substrate recognition are labeled 
accordingly.  ).  Molecules on the left indicate which β-
functionality is accepted by the KS domain from an upstream 
ACP.  Each consensus sequence was determined by alignment of 
at least 25 individual sequences.  The more hydrophobic olefin 
and methylene functionalities generally coincide with more 
hydrophobic residues at positions 1 and 2 while ketone and 
hydroxyl groups tend to prefer hydrophilic residues at these 
positions. 
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position from an upstream ACP.  Consensus sequences derived from this data revealed some 
intriguing trends (Figure 33. Consensus sequences for each of the four KS active site pocket 
residues of interest (see Figure 32. Crystal structure of the DEBS module 3 KS active site pocket 
(PDB: 2QO3).  Active site cysteine indicated by a green sphere.  The four loop residues thought to 
play a role in substrate recognition are labeled accordingly.  ).  Molecules on the left indicate 
which β-functionality is accepted by the KS domain from an upstream ACP.  Each consensus 
sequence was determined by alignment of at least 25 individual sequences.  The more 
hydrophobic olefin and methylene functionalities generally coincide with more hydrophobic 
residues at positions 1 and 2 while ketone and hydroxyl groups tend to prefer hydrophilic residues 
at these positions).  Firstly, it is not immediately obvious that this region of the active site pocket 
is able to distinguish between β-keto and β-hydroxyl functionalities.  In contrast, positions 1 and 
2 may play a critical role in selecting between hydrophobic and hydrophilic groups.  For the more 
polar ketone and hydroxyl groups, these two positions are dominated by hydrophilic residues 
capable of hydrogen bonding while KS domains that natively accept olefin and methylene 
functionalities generally possess more hydrophobic amino acids at these positions.  For example, 
close examination of these residues in fluvirucin module 3, which accepts a β-hydroxyl group, and 
module 5, which accepts a β-methylene, reveals a similar trend.  Module 3 KS bears a glycine at 
position 1 and threonine at position 2 while module 5 KS contains an alanine at position 1 and a 
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phenylalanine at position 2.  If either of these KS domains exhibit strict selection for its native 
substrate, introducing more hydrophobicity to module 3 and more hydrophilicity to module 5 may 
serve to reverse its substrate tolerances. 
In a broader sense, the consensus sequences for each β-functionality will be introduced, 
via site-directed mutagenesis, to each fluvirucin KS domain that displays high substrate selectivity 
from section 5.3.1.  The impact of these mutations will be readily observed using our fluorescence 
transfer assay.  Any changes to the fluorescence pattern between the unmodified and mutated 
KS domains will be confirmed by tandem proteolysis-LCMS.  Mutant KS domains with altered or 
relaxed substrate selectivity relative to wild-type will join the kinetically-controlled KS domains 
for production of novel fluvirucin analogs. 
If grafting consensus sequences onto the selective KS domains results in little change to 
substrate tolerances, alternative strategies are in place to further explore the role of this pocket 
region in substrate recognition.  The 20+ sequences used to generate each consensus sequence 
above come from a wide variety of PKS systems at vastly different positions along each assembly 
line.  Therefore, it may be worth adopting narrower search criteria for modification of KS-
selectivities.  In lieu of consensus sequences, we will search within each subset of available 
sequences for KS domains that natively accept substrates with the highest similarities, in terms of 
length, α-functionality, and more distal functionality to the natural fluvirucin substrates.  For 
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instance, the natural substrate of DEBS module 4 is a tetraketide containing α-methyl and β-keto 
functionalities, and a β-keto form of the fluvirucin module 4 substrate would bear significant 
resemblance to this. Therefore, the DEBS module 4 active site pocket sequence (MNGQ), which 
has little in common with the fluvirucin module 4 sequence (GTQT), is a potential alternative to 
the consensus sequence (TNGQ).  Given the projected flexibility of the loop which harbors the 
target residues and sequence variability observed for each type of β-functionality, it is probable 
that even minor changes to this region will have a dramatic impact on KS-selectivities.   
As a second alternative strategy, we will broaden our pursuit using saturation 
mutagenesis to explore full sequence variation at positions 1 and 2 of the target active site pocket 
region.  The resulting mutant KS domains will be expressed and subsequently bound to Ni-NTA 
beads or functionalized plates.  After thorough washing, the bound KS domain will be incubated 
with substrate(s) bearing the desired β -functionalities followed by addition of an untagged, 
fluorescent ACP.  The mutant KS domains will then be eluted from the Ni-NTA and the degree of 
ACP to KS fluorescence transfer will be determined by PAGE analysis.  Gels will then be stained to 
confirm that any lack of fluorescence is the result of active site acylation with substrate and not 
poor expression of the KS domain.  As above, any mutant KS domains that show altered or 
broadened substrate tolerance will be utilized in section 5.3.3 for optimization of fluvirucin analog 
production.  Together with the more targeted strategies described above, we are well positioned 
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to clearly define a role for these residues in substrate recognition which will aid in future 
exploration of KS active site pockets well beyond the fluvirucin system.       
5.3.3 Macrolactam Production from Engineered Fluvirucin PKS  
In order to reconstitute the biosynthesis of fluvirucin B1 aglycone and further to produce 
its analogs, we will utilize the constructs and information generated from native KSATs 
selectivities (section 5.3.1) and bioinformatic analyses (section 5.3.2) to systematically examine 
the relative contributions of KS substrate selectivity and disruption of protein-protein interactions 
on fluvirucin analog production.  We envision three possible outcomes from the work described 
in previous chapters.  Firstly, it may be the case that all KS domains in the fluvirucin PKS are 
kinetically controlled, in which case broad substrate tolerance will be observed across the board.  
In the unlikely event that this is the case, we still plan to explore the role of active site pocket 
residues as described in section 5.3.2.  Any changes to substrate selectivity arising from these 
studies will provide critical insight for other PKSs where KS substrate selectivity is more tightly 
regulated.  Should we instead observe the opposite and equally unlikely case where all KS domains 
exhibit high selectivity for a particular substrate, we stand to gain maximal insight as to the role 
played by the aforementioned active site pocket residues in substrate recognition.  While we are 
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prepared for either of these two extremes, the most likely scenario for chain transfer in the 
fluvirucin PKS involves a combination of these mechanisms. 
In any case, we have reconstructed the full fluvirucin PKS on three separate plasmids with 
unique resistance markers.  The first two plasmids contain fluA (modules 1 and 2, Figure 34) and 
fluB (modules 3 and 4, Figure 35) while the third harbors fluC (module 5, Figure 36) and the genes 
necessary for methylmalonyl-CoA production (Figure 36).  Using these three constructs, we will 
attempt to reconstitute the fluvirucin PKS pathway in E. coli.  This versatile host has been 
instrumental in much of the DEBS work and has proved quite tolerant of fluvirucin-related genes 
in our preliminary work with this system.  Despite the many advantages of using E. coli for 
fluvirucin production, this host does have some limitations and a plan to tackle these potential 
issues is essential. 
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Figure 34. The plasmid map of pTL-F01b 
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Figure 35. The plasmid map of pTL-F02 
 107 
 
5.3.3.1 Reconstituting Fluvirucin B1 Aglycone Production in E. Coli 
The most challenging part of using a heterologous host for fluvirucin production will be 
rendering the PKS functional.  This system utilizes methylmalonyl- and ethylmalonyl-CoA as 
extender units, both of which are produced at very low levels, if at all, in E. coli.  Luckily, the issue 
of methylmalonyl-CoA production has previously been solved for the DEBS system via 
Figure 36. The plasmid map of pTL-F03p 
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introduction of propionyl-CoA carboxylase (PCC) and related genes.11 - 12   We will rely on this 
technique for the fluvirucin PKS, but an equivalent means of ethylmalonyl-CoA generation will 
likely necessitate further engineering of the host.  We have devised several complementary 
strategies for tackling this issue including (1) exploiting the relaxed substrate tolerance of PCC, 
and (2) introduction of crotonyl-CoA carboxylase/reductase (CCR).   
Propionyl-CoA Carboxylase: As the most straightforward of these potential solutions, we 
may be able to simply use the same enzymes responsible for methylmalonyl-CoA production.  It 
has been observed that PCC has moderately relaxed substrate selectivity and will catalyze, albeit 
with lower efficiency, carboxylation of butyryl-CoA. 13 , 14  We will attempt to generate both 
methylmalonyl- and ethylmalonyl-CoA by addition of propionate and butyrate, respectively, to 
our engineered E. coli cultures.  Since propionate is converted faster than butyrate, we plan to 
add the latter in excess.  Analysis of lysates by LC-MS will help determine the extent to which each 
species is formed and modifications to the addition ratio will be made accordingly.    
Crotonyl-CoA Carboxylase Reductase: Our backup plan if the PCC method proves 
unsuccessful will be to employ a natural enzyme involved in ethylmalonyl-CoA biosynthesis in S. 
collinus, CCR. 15,16  This strategy has been used previously in Streptomyces to incorporate a single 
ethylmalonate into the backbone of 6-deoxyerythronolide B. 17   By adding the appropriate 
precursors to an engineered S. erythraea strain overproducing CCR, they were able to 
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demonstrate incorporation of ethylmalonate.  A similar strategy will be attempted in our 
engineered E. coli system to provide the correct extender units for fluvirucin biosynthesis.  As an 
interesting side note, the same research team that produced the ethyl analog of 6-
deoxyerythronolide B observed that the ethylmalonate-specific AT domain would accept 
methylmalonate under conditions where ethylmalonyl-CoA was unavailable.17  If the fluvirucin AT 
domains exhibit a similar tolerance for methylmalonyl-CoA, the methylated form of the final 
product will suffice for all downstream experiments.          
With a functional strategy for extender unit construction in place, we will begin assessing 
fluvirucin output from our engineered E. coli strain.  The N-acetylcysteamine thioester of β-
alanine (β-Ala-SNAc) will serve as the starter unit for PKS priming.  A series of 100 ml cultures of 
appropriately engineered BAP1, an E. coli variant with a phosphopantetheinyl transferase 
embedded in the genome, will be incubated with β-Ala-SNAc at concentrations ranging from 1 
mM to 1 M to determine the optimal conditions for fluvirucin production.  Small molecule output 
will be assayed using LC-MS following organic extraction of each lysate.  Further optimization of 
fermentation parameters will be accomplished using additional variables such as culture volume, 
incubation temperature, and time.  Ultimately, the maximal yield ascertained in these studies will 
provide the benchmark for comparison to all mutant forms.   Although it is just the beginning of 
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our work with this system, successful production of fluvirucin B1 will represent the first 
demonstration of heterologous macrolactam generation in E. coli. 
We are fully aware that reconstitution of the fluvirucin PKS pathway in E. coli may not be 
possible.  Although we are thoroughly committed to this host for its genetic simplicity, fast 
growth, and the countless tools available for its manipulation, alternate plans are in place if at any 
point it becomes clear that our efforts are unproductive.  Other bacteria, including S. coelicolor 
and S. lividans have also been used to heterologously produce polyketides and may require less 
host-engineering than E. coli should this pose a problem.18   In addition, we will explore the 
possibility of a cell-free synthesis of fluvirucin using synthetically-derived starter and extender 
units.  Although not equivalent to cell-based fluvirucin biosynthesis, this strategy may afford the 
desired information regarding the engineering obstacles with little background noise arising from 
unrelated cellular metabolites.   
5.3.3.2 Mutational Inactivation of Individual Domains for Increased Product Yield 
During the biosynthesis of fluvirucin B1, thirteen unique tailoring domains are involved in 
β-carbon processing.  In contrast, DEBS relies on only seven of these enzymes for 6-
deoxyerythronolide B production despite harboring an extra module compared to the fluvirucin 
PKS.   Therefore, if our goal is to manipulate small molecule structure without disrupting native 
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protein-protein interactions, mutational inactivation of fluvirucin PKS domains nearly doubles the 
product landscape.  It has been said that the key to successful combinatorial methods in natural 
product biosynthesis lies in the discovery of higher-yielding engineering strategies.19 This section 
of our research program will systematically illustrate the benefits of simple mutagenesis to control 
polyketide structure (Figure 37).  In addition, the relative product yields from each single-point 
mutant will begin to uncover when, and to what extent, substrate selectivity plays a role in the 
Figure 37. Schematic diagram of our domain deletion-based engineering strategy for 
fluvirucin analog production.  Active site mutagenesis of KR, DH, and ER domains will result 
in site-specific incorporation of ketone, hydroxyl, and olefin functionalities respectively.  This 
strategy eliminates the need for introduction of heterologous PKS components thus 
circumventing the disruption of protein-protein interactions, a major engineering hurdle.   
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flow of intermediates along the assembly line. It should be noted that our strategy for mutational 
activation is almost exclusively based on work with similar PKS assemblies.  However, we are 
prepared to take a more exploratory route (i.e. random mutagenesis, alanine scanning, etc.) 
should the need arise. 
KR domain inactivation: We will initially focus mutagenesis efforts on conserved NADPH 
binding residues for inactivation of ketoreductase domains as described in the preliminary studies 
section.  Alternatively, most active KR domains harbor a highly conserved catalytic triad, 
Ser/Tyr/Lys, which serves to activate the electrophilic carbonyl carbon toward hydride attack.  Any 
issues encountered with cofactor binding mutants may be resolved by additionally altering these 
residues.  Disruption of the catalytic triad may also improve kinetics in these modified systems if 
KR-recognition of the ACP-bound intermediates slows intermodular transfer.  Combinations of 
mutations to both the NADPH binding site and catalytic residues will be examined to determine 
optimal inactivation parameters.   
DH domain inactivation: Although not yet rigorously studied in modular polyketide 
synthases, based on work with analogous fatty acid synthases, dehydratase activity likely relies 
heavily on a conserved histidine residue acting as a general base on the proton of the β-hydroxyl 
group during dehydration. We expect that mutating this residue to any hydrophobic amino acid 
such as alanine or leucine will abolish activity.   
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ER domain inactivation: Similar to KR domains, enoyl reductases require an NADPH 
cofactor for activity.  Both single and multiple mutations within this binding site will be examined 
to determine the most favorable configuration as above.  
Each of the thirteen mutants will be individually assayed using the optimized parameters 
for wild-type fluvirucin production elucidated in section 5.3.3.1 (Figure 38).  Yields of the 
engineered products, relative to the wild-type fluvirucin, will be determined by LC-MS using an 
internal standard.  Although we do not expect the ionization potentials of these products to be 
Figure 38. Structures of the thirteen fluvirucin analogs possible from single domain 
inactivations.  Each mutation results in site specific modification of macrolactam structure.  
Relative yields of these products will provide vital information as to the relative contributions 
of the two primary obstacles in polyketide engineering. 
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vastly different, standard curves will be prepared for added assurance.  Any polyketide products 
generated in high enough quantities upon scale-up will be analyzed by 1D and 2D NMR to uncover 
any stereochemical trends as they relate to intermodular shuttling of intermediates.  We are 
aware that, in some cases, the thioesterase domain may not be able to efficiently cyclize the 
intended product, resulting in unexpectedly low yields.  Every effort will be made to identify and 
quantitate hydrolysis products, and plans are in place to utilize alternative thioesterase domains 
should the need arise.  Our overriding goal is to meet or exceed the highest yields obtained with 
the engineered DEBS system (~70% of wild type) for all single mutants of the fluvirucin PKS. 19,20 
At these levels, we can confidently state that we have overcome the primary polyketide 
engineering hurdles and that realization of functional combinatorial biosynthesis is well within 
our grasp. 
5.3.4 Engineering FAS-like PKS into Iterative PKS 
Similarities between FASs and modular PKS has been studied from the level of the 
individual reaction mechanisms to the structures of each catalytic domains and the architectural 
organization of the entire enzymatic complexes21 , 22 , and furthermore, the evolutionary links 
between FAS and PKS has been emphasized by comprehensive phylogenetic analyses to show  
they may have a common origin.23 Therefore, it is very reasonable to explore the possibility to 
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engineer a PKS module into an iterative FAS system, and the successful result could be applied 
into metabolic engineering or biofuel production. 
In 2012, Khosla and coworkers have “reprogrammed” module 3 of DEBS to catalyze two 
successive rounds of chain elongation. 24 However, they could not observe products more than 
two iterations, and they hypothesized that the active site of KS3 may not be able to accommodate 
substrate longer than triketide. Similarly, Mohanty and colleagues conducted bioinformatic 
analyses on 217 pure modular KS domains, 82 pure iterative domains, 19 enediyne, 43 trans-type 
and 34 KS domains from hybrid NRPS-PKS clusters, 25  and they have discovered two crucial 
positions may govern the chain length in different iterative PKSs. They also combined the 
structural information of FAS and PKS to deduce that the size of substrate cavity in KS hold the 
key to fully engineer a PKS into a FAS.  
We believe that fluvirucin PKS system provides a unique opportunity and potential to be 
explored for this purpose. Not only four out of five modules possess the similarity to FAS, but also 
they are subdivided into two distinct group which could be useful in terms of bioinformatic 
analyses and in vitro experiments. 
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5.4 Summary 
In this thesis, I seek to examine the relative contributions of the two primary causes of 
low yields in polyketide engineering, substrate selectivity and disruption of protein-protein 
interactions, issues that have severely limited drug discovery and diversification programs for the 
past several decades.  In contrast to most traditional PKS systems used for metabolic engineering 
efforts, the fluvirucin PKS is composed primarily of fatty acid synthase-like modules which contain 
all three β-processing domains (KR, DH, and ER).  These enzymes are solely responsible for the 
oxidation state of every other carbon on the polyketide chain and, therefore, provide enormous 
potential for controlling product variation through genetic engineering.  Most importantly, 
alterations to polyketide structure can be achieved by simple mutagenesis of key amino acids 
which leaves the three-dimensional architecture and all native protein-protein recognition motifs 
intact.  This is in stark contrast to other, well-studied systems such as DEBS, where obtaining the 
desired level of product diversity requires the introduction of heterologous domains and modules 
which are not necessarily evolved to communicate with the native components.   
Our strategy with the fluvirucin PKS effectively eliminates the disruption of protein-
protein interactions as an engineering hurdle. As a result, we are uniquely positioned to tackle 
the second hurdle, substrate selectivity, in isolation.  This challenge requires a thorough 
understanding of chain transfer mechanisms between ACP and the downstream KS domain.  Using 
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the fluorescence assay for KS substrate selectivity and guided by recent structural data, we will 
both determine the native substrate tolerance for each fluvirucin KS domain and attempt to alter 
or broaden selectivity in those domains exhibiting inherent, thermodynamically-controlled 
substrate recognition. By eliminating both of these engineering obstacles, we aspire to obtain 
near wild type production levels of fluvirucin B1 analogs.  In cases where low yields persist, we 
aim to uncover alternative engineering obstacles and ultimately offer a set of universal guidelines 
for polyketide structure diversification.   
Successful execution of the proposed research program will lead to improved 
understanding of chain transfer mechanisms, more clearly-defined approaches for domain 
deletion, and the necessary foundation for practical combinatorial biosynthesis.  To illustrate the 
latter, future efforts will focus on design and implementation of experiments where high-yielding 
single KR, DH, and ER mutants are combined to produce usable quantities of novel macrolactams. 
Realization of this goal will permit greatly expanded exploration of polyketide functionality and 
amass an abundance of diverse macrolide scaffolds for building the next generation of small 
molecule therapeutics, and even elucidate the evolution relationship between FASs and PKSs. 
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